Subsidiary_NN and_CC associated_VBN undertakings_NNS Principal_NN subsidiary_NN undertakings_NNS The_DT information_NN provided_VBN below_RB is_VBZ given_VBN for_IN principal_JJ subsidiary_NN undertakings_NNS in_IN accordance_NN with_IN Section_NN 231_CD 5_CD a_DT of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
A_DT full_JJ list_NN will_MD be_VB appended_VBN to_TO the_DT companys_NNS next_JJ annual_JJ return_NN ._.
Country_NN of_IN operation_NN Activity_NN and_CC incorporation_JJ %_NN owned_VBN United_NNP Kingdom_NNP Smith_NNP &_CC Nephew_NNP Healthcare_NNP Limited_NNP Medical_NNP devices_NNS United_NNP Kingdom_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Medical_NNP Limited_NNP Medical_NNP devices_NNS United_NNP Kingdom_NNP 100_CD %_NN TJ_NNP Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS United_NNP Kingdom_NNP 100_CD %_NN Continental_NNP Europe_NNP Smith_NNP &_CC Nephew_NNP GmbH_NNP Medical_NNP devices_NNS Austria_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP SA-NV_NNP Medical_NNP devices_NNS Belgium_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP A_NNP S_NNP Medical_NNP devices_NNS Denmark_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP OY_NNP Medical_NNP devices_NNS Finland_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP SA_NNP Medical_NNP devices_NNS France_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP GmbH_NNP Medical_NNP devices_NNS Germany_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS Ireland_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Srl_NNP Medical_NNP devices_NNS Italy_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP BV_NNP Medical_NNP devices_NNS Netherlands_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP A_NNP S_NNP Medical_NNP devices_NNS Norway_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Lda_NNP Medical_NNP devices_NNS Portugal_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP SA_NNP Medical_NNP devices_NNS Spain_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP AB_NNP Medical_NNP devices_NNS Sweden_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP AG_NNP Medical_NNP devices_NNS Switzerland_NNP 100_CD %_NN America_NNP Smith_NNP &_CC Nephew_NNP Inc_NNP Medical_NNP devices_NNS Canada_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP SA_NNP fide_VBD CV_NNP Medical_NNP devices_NNS Mexico_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Inc_NNP Medical_NNP devices_NNS Puerto_NNP Rico_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Inc_NNP Medical_NNP devices_NNS United_NNP States_NNPS 100_CD %_NN Africa_NNP ,_, Asia_NNP and_CC Australasia_NNP Smith_NNP &_CC Nephew_NNP Pty_NNP Limited_NNP Medical_NNP devices_NNS Australia_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS Hong_NNP Kong_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Healthcare_NNP Limited_NNP Medical_NNP devices_NNS India_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP KK_NNP Medical_NNP devices_NNS Japan_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS Korea_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Healthcare_NNP Sdn_NNP Berhad_NNP Medical_NNP devices_NNS Malaysia_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS New_NNP Zealand_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Pte_NNP Limited_NNP Medical_NNP devices_NNS Singapore_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS South_NNP Africa_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP Limited_NNP Medical_NNP devices_NNS Thailand_NNP 100_CD %_NN Smith_NNP &_CC Nephew_NNP FZE_NNP Medical_NNP devices_NNS United_NNP Arab_NNP Emirates_NNPS 100_CD %_NN Owned_VBN indirectly_RB by_IN the_DT parent_NN company_NN Principal_NN associated_VBN undertakings_NNS ,_, joint_JJ ventures_NNS and_CC other_JJ arrangements_NNS The_DT group_NN owns_VBZ 50_CD %_NN of_IN BSN_NNP Medical_NNP GmbH_NNP &_CC Co_NNP KG_NNP ,_, a_DT medical_JJ devices_NNS company_NN ,_, incorporated_VBN in_IN Germany_NNP which_WDT has_VBZ been_VBN included_VBN in_IN the_DT consolidated_JJ accounts_NNS as_IN a_DT joint_JJ venture_NN ._.
The_DT group_NN owns_VBZ 21.5_CD %_NN of_IN AbilityOne_NNP Corporation_NNP ,_, a_DT supplier_NN of_IN rehabilitation_NN products_NNS to_TO hospitals_NNS ,_, nursing_VBG homes_NNS and_CC clinics_NNS ,_, incorporated_VBN in_IN the_DT United_NNP States_NNPS which_WDT has_VBZ been_VBN included_VBN in_IN the_DT consolidated_JJ accounts_NNS as_IN an_DT associated_VBN undertaking_NN ._.
In_IN 2001_CD the_DT group_NN had_VBD interests_NNS in_IN two_CD joint_JJ arrangements_NNS with_IN Advanced_NNP Tissue_NNP Sciences_NNPS ,_, Inc._NNP one_CD relating_VBG to_TO products_NNS for_IN the_DT treatment_NN of_IN diabetic_JJ foot_NN ulcers_NNS and_CC other_JJ wound_NN indications_NNS ,_, and_CC the_DT other_JJ for_IN cartilage_NN replacement_NN ._.
During_IN the_DT year_NN the_DT group_NN acquired_VBD the_DT interests_NNS it_PRP did_VBD not_RB already_RB own_VB in_IN the_DT joint_JJ arrangements_NNS from_IN Advanced_NNP Tissue_NNP Sciences_NNPS ,_, Inc._NNP 52_CD Smith_NNP &_CC Nephew_NNP 2002_CD Information_NN for_IN shareholders_NNS Financial_JJ calendar_NN Shareview_NNP To_TO view_VB information_NN about_IN your_PRP$ shareholdings_NNS on_IN the_DT internet_NN ,_, register_NN at_IN www_NN ._.
com_NN ,_, the_DT Lloyds_NNP Annual_JJ General_NNP Meeting_VBG 29_CD April_NNP 2003_CD TSB_NNP enquiry_NN and_CC portfolio_NN management_NN service_NN for_IN Payment_NN of_IN 2002_CD final_JJ dividend_NN 16_CD May_NNP 2003_CD shareholders_NNS ._.
When_WRB you_PRP have_VBP registered_VBN for_IN shareview_NN you_PRP Interim_VBP results_NNS announced_VBD 31_CD July_NNP 2003_CD will_MD also_RB be_VB able_JJ to_TO register_VB your_PRP$ proxy_NN instructions_NNS online_VBP Payment_NN of_IN 2003_CD interim_JJ dividend_NN 14_CD November_NNP 2003_CD and_CC elect_VB to_TO receive_VB future_JJ shareholder_NN communications_NNS Full_NNP year_NN results_NNS announced_VBD early_JJ February_NNP 2004_CD via_IN our_PRP$ website_JJ www_NN ._.
Annual_JJ report_NN posted_VBD early_RB March_NNP 2004_CD Annual_JJ General_NNP Meeting_VBG 5_CD May_NNP 2004_CD Shareholder_NN Enquiries_NNS For_IN information_NN about_IN the_DT AGM_NNP ,_, shareholdings_NNS ,_, dividends_NNS and_CC changes_NNS to_TO personal_JJ details_NNS Final_JJ dividend_NN all_DT shareholders_NNS should_MD contact_VB :_: Lloyds_NNP TSB_NNP Registrars_NNPS ,_, The_DT ordinary_JJ shares_NNS will_MD trade_VB ex-dividend_NN on_IN both_DT the_DT The_DT Causeway_NNP ,_, Worthing_NNP ,_, West_NNP Sussex_NNP ,_, BN99_NNP 6DS_NNP ._.
London_NNP and_CC New_NNP York_NNP Stock_NNP Exchanges_NNPS from_IN 16_CD April_NNP 2003_CD Telephone_NNP 0870 600 3996_CD ._.
and_CC the_DT record_NN date_NN will_MD be_VB 22_CD April_NNP 2003_CD in_IN respect_NN of_IN this_DT years_NNS proposed_VBN final_JJ dividend_NN to_TO be_VB paid_VBN on_IN 16_CD May_NNP 2003_CD ._.
American_JJ depositary_NN receipts_NNS ADRs_NNPS In_IN the_DT US_NNP ,_, the_DT companys_NNS ordinary_JJ shares_NNS are_VBP traded_VBN in_IN the_DT Ordinary_NNP shares_NNS form_NN of_IN American_JJ Depositary_NNP Shares_NNP ,_, evidenced_VBN by_IN ADRs_NNS ,_, Payment_NN of_IN cash_NN dividends_NNS Shareholders_NNS who_WP wish_VBP their_PRP$ and_CC trade_NN under_IN the_DT symbol_NN SNN_NNP ._.
Each_DT American_JJ Depositary_NNP dividends_NNS to_TO be_VB paid_VBN directly_RB to_TO a_DT bank_NN or_CC building_NN society_NN Share_NN represents_VBZ ten_NN ordinary_JJ shares_NNS ._.
Bank_NNP of_IN New_NNP York_NNP and_CC who_WP have_VBP not_RB already_RB completed_VBN a_DT BACS_NNP mandate_NN is_VBZ the_DT authorised_JJ depositary_JJ bank_NN for_IN the_DT companys_NNS ADR_NNP should_MD contact_VB the_DT companys_NNS registrars_NNS ._.
A_DT Global_JJ BuyDIRECT_NNP plan_NN is_VBZ available_JJ for_IN US_NNP residents_NNS ,_, enabling_VBG investment_NN directly_RB in_IN ADRs_NNS with_IN Dividend_NN re-investment_JJ plan_NN The_DT company_NN has_VBZ a_DT dividend_NN reduced_VBN brokerage_NN commissions_NNS and_CC service_NN costs_NNS ._.
For_IN re-investment_JJ plan_NN that_WDT offers_VBZ shareholders_NNS the_DT opportunity_NN further_RBR information_NN on_IN Global_JJ BuyDIRECT_NNP contact_NN :_: Bank_NNP to_TO invest_VB their_PRP$ cash_NN dividends_NNS in_IN Smith_NNP &_CC Nephew_NNP shares_NNS ,_, of_IN New_NNP York_NNP on_IN 1-888-BNY-ADS_NNP toll-free_JJ or_CC visit_NN which_WDT are_VBP purchased_VBN in_IN the_DT market_NN at_IN competitive_JJ dealing_VBG www_NN ._.
Application_NN forms_NNS for_IN re-investing_VBG the_DT 2002_CD final_JJ dividend_NN are_VBP available_JJ from_IN Lloyds_NNP TSB_NNP Registrars_NNPS who_WP Smith_NNP &_CC Nephew_NNP ADR_NNP price_NN The_DT companys_NNS ADR_NNP price_NN is_VBZ administer_VB the_DT plan_NN on_IN behalf_NN of_IN the_DT company_NN ._.
Applications_NNS quoted_VBD daily_RB in_IN the_DT Wall_NNP Street_NNP Journal_NNP and_CC can_MD be_VB obtained_VBN for_IN re-investment_NN should_MD be_VB returned_VBN to_TO the_DT companys_NNS from_IN the_DT official_JJ New_NNP York_NNP Stock_NNP Exchange_NNP website_JJ registrars_NNS by_IN 29_CD April_NNP 2003_CD ._.
www_NN ._.
UK_NNP capital_NN gains_NNS tax_NN For_IN the_DT purposes_NNS of_IN capital_NN gains_NNS tax_NN ADR_NNP Enquiries_NNPS All_DT enquiries_NNS regarding_VBG ADR_NNP holder_NN accounts_VBZ the_DT price_NN of_IN ordinary_JJ shares_NNS on_IN 31_CD March_NNP 1982_CD was_VBD 35.04_CD p._NN and_CC payment_NN of_IN dividends_NNS should_MD be_VB addressed_VBN to_TO Bank_NNP of_IN New_NNP York_NNP ,_, 620_CD Avenue_NNP of_IN the_DT Americas_NNPS ,_, New_NNP York_NNP ,_, Smith_NNP &_CC Nephew_NNP share_NN price_NN The_DT companys_NNS share_VBP price_NN is_VBZ New_NNP York_NNP 10011_CD ._.
quoted_VBN daily_JJ in_IN national_JJ newspapers_NNS ,_, as_RB well_RB as_IN on_IN Ceefax_NNP and_CC Teletext_NNP and_CC at_IN www_NN ._.
com_NN where_WRB Annual_JJ General_NNP Meeting_VBG it_PRP is_VBZ updated_VBN at_IN intervals_NNS throughout_IN the_DT day_NN ._.
The_DT Financial_NNP The_DT companys_NNS 66th_VBP Annual_JJ General_NNP Meeting_VBG is_VBZ to_TO be_VB held_VBN Times_NNP Cityline_NNP Service_NNP ,_, telephone_NN 0906 0034043_CD ,_, provides_VBZ on_IN 29_CD April_NNP 2003_CD at_IN 10.30_CD am_VBP at_IN the_DT Institute_NNP of_IN Mechanical_NNP an_DT up_RB to_TO the_DT minute_JJ share_NN price_NN ._.
A_DT fee_NN is_VBZ charged_VBN for_IN this_DT Engineers_NNS ,_, One_CD Birdcage_NN Walk_VBP ,_, London_NNP ,_, SW1H_NNP 9JJ_NNP ._.
of_IN the_DT meeting_NN is_VBZ enclosed_VBN with_IN an_DT accompanying_JJ letter_NN from_IN the_DT Chairman_NNP ._.
Low-cost_JJ dealing_VBG service_NN A_DT postal_JJ and_CC telephone_NN facility_NN that_WDT provides_VBZ a_DT simple_JJ low-cost_JJ method_NN of_IN buying_NN and_CC Registered_NNP office_NN selling_NN Smith_NNP &_CC Nephew_NNP shares_NNS is_VBZ available_JJ through_IN Hoare_NNP Smith_NNP &_CC Nephew_NNP plc_NN ,_, 15_CD Adam_NNP Street_NNP ,_, Govett_NNP Limited_NNP ._.
For_IN information_NN contact_NN Hoare_NNP Govett_NNP London_NNP WC2N_NNP 6LA_NNP Ltd._NNP 250_CD Bishopsgate_NNP ,_, London_NNP ,_, EC2M_NNP 4AA_NNP ._.
Telephone_NNP Registered_NNP in_IN England_NNP No._NN ._.
Advisers_NNP Smith_NNP &_CC Nephew_NNP Corporate_NNP ISA_NNP The_DT company_NN has_VBZ a_DT Solicitors_NNS :_: Ashurst_NNP Morris_NNP Crisp_NNP corporate_JJ Individual_NNP Savings_NNPS Account_NNP ISA_NNP administered_VBN by_IN Pinsent_NNP Curtis_NNP Biddle_NNP Lloyds_NNP TSB_NNP Registrars_NNPS ._.
For_IN information_NN about_IN this_DT service_NN Auditors_NNS :_: Ernst_NNP &_CC Young_NNP LLP_NNP please_VB contact_VB their_PRP$ helpline_NN on_IN telephone_NN 0870 2424 244_CD ._.
Stockbrokers_NNS :_: Cazenove_NNP &_CC Co_NNP Dresdner_NNP Kleinwort_NNP Wasserstein_NNP Trademarks_NNPS The_DT product_NN names_NNS referred_VBD to_TO in_IN this_DT document_NN are_VBP trademarks_NNS owned_VBN by_IN or_CC licensed_VBN to_TO members_NNS of_IN the_DT Smith_NNP &_CC Nephew_NNP group_NN ._.
Designed_VBN and_CC produced_VBN by_IN Fitch_NNP :_: London_NNP ._.
Board_NNP photography_NN by_IN Sven_NNP Seiffert_NNP ._.
pp_NN You_PRP have_VBP access_NN to_TO more_JJR information_NN from_IN the_DT following_JJ sources_NNS :_: Board_NNP Group_NNP Executive_NNP Committee_NNP biographies_NNS For_IN further_JJ biographies_NNS ,_, visit_NN :_: www_NN ._.
html_NN Presentations_NNS For_IN presentations_NNS to_TO analysts_NNS and_CC shareholders_NNS ,_, visit_NN :_: www_NN ._.
html_NN You_PRP are_VBP here_RB :_: Annual_JJ Report_NNP and_CC Accounts_NNPS Contents_NNP Financial_NNP highlights_VBZ Chairmans_NNP statement_NN Chief_NNP Executives_NNS statement_NN Board_NNP &_CC Group_NNP Executive_NNP Committee_NNP Financial_NNP review_NN Corporate_JJ social_JJ responsibility_NN Corporate_JJ governance_NN Remuneration_NNP report_NN Directors_NNS responsibilities_NNS Auditors_NNS report_VBP Group_NNP profit_NN and_CC loss_NN account_NN Group_NNP balance_NN sheet_NN Group_NNP cash_NN ow_NN statement_NN Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Movement_NNP in_IN shareholders_NNS funds_NNS Parent_NNP company_NN balance_NN sheet_NN Accounting_NN policies_NNS Notes_NNS to_TO the_DT accounts_NNS Group_NNP five_CD year_NN summary_NN Subsidiary_NNP and_CC associated_VBN undertakings_NNS Information_NN for_IN shareholders_NNS Available_JJ as_IN a_DT printed_VBN document_NN or_CC online_NN at_IN :_: www_NN ._.
com_NN investors_NNS annualreport2002_JJ Sustainability_NN report_NN For_IN further_JJ information_NN on_IN sustainability_NN and_CC to_TO access_VB our_PRP$ report_NN ,_, visit_NN :_: www_NN ._.
com_NN sustainability2002_CD Shareholder_NN information_NN For_IN further_JJ up-to-date_JJ shareholder_NN information_NN ,_, visit_NN :_: www_NN ._.
html_NN For_IN up-to-minute_JJ share_NN price_NN information_NN ,_, visit_NN :_: www_NN ._.
com_NN Smith_NNP &_CC Nephew_NNP plc_NN investors_NNS financial_JJ data_NNS ._.
html_NN 15_CD Adam_NNP Street_NNP For_IN press_NN releases_NNS and_CC latest_JJS business_NN information_NN ,_, visit_NN :_: London_NNP WC2N_NNP 6LA_NNP www_NN ._.
com_NN Delivering_NNP Sustainable_NNP Growth_NNP 2002_CD Report_NNP to_TO Shareholders_NNS and_CC Summary_NNP Financial_NNP Statement_NNP Financial_NNP highlights_VBZ 2002_CD 2001_CD million_CD million_CD Turnover_NN 1,109.9_CD 1,081.7_CD Profit_NN before_IN taxation_NN :_: before_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS 209.9_CD 180.9_CD after_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS 177.9_CD 193.6_CD Earnings_NNS per_IN share_NN before_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS 16.02_CD p_NN 13.96_CD p_NN Earnings_NNS per_IN share_NN after_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS 12.11_CD p_NN 14.07_CD p_NN Dividends_NNS per_IN share_NN 4.80_CD p_NN 4.65_CD p_NN We_PRP are_VBP committed_VBN to_TO setting_VBG new_JJ standards_NNS in_IN patient_JJ treatment_NN and_CC recovery_NN ,_, Contents_NNP Directors_NNS report_VBP 01_CD Financial_JJ highlights_VBZ 02_CD Chairmans_NNPS statement_NN PERFORMANCE_NN 04_CD Chief_NNP Executives_NNS statement_NN OUR_NNP PERFORMANCE_NN CULTURE_NN IS_VBZ 10_CD Board_NNP &_CC Group_NNP Executive_NNP Committee_NNP DRIVING_NNP GLOBAL_NNP SALES_NNP GROWTH_NN 12_CD Corporate_JJ social_JJ responsibility_NN AND_CC MARGIN_NN IMPROVEMENT_NN ._.
14_CD Corporate_JJ governance_NN 15_CD Summary_NNP remuneration_NN report_NN Accounts_NNPS 16_CD Auditors_NNS statement_NN 17_CD Summary_NNP financial_JJ statement_NN 19_CD Information_NN for_IN shareholders_NNS 20_CD Group_NNP five_CD year_NN summary_NN 1,135_CD 17.8_CD 16.02_CD 1,120_CD 1,110_CD 17.1_CD 1,082_CD 1,053_CD 16.4_CD 13.96_CD 1,084_CD 15.1_CD 14.7_CD 978_CD 12.19_CD 912_CD 10.88_CD 800_CD 9.61_CD 714 1998 1999 2000_CD 2001 2002 1998 1999_CD 2000 2001 2002 1998_CD 1999 2000 2001 2002_CD Group_NNP Turnover_NN Group_NNP Margins_NNS %_NN Earnings_NNS Per_IN Share_NN Continuing_VBG Sales_NNS Before_IN goodwill_NN before_IN goodwill_NN Million_NNP amortisation_NN and_CC amortisation_NN and_CC exceptional_JJ Items_NNS exceptional_JJ items_NNS Pence_NNP as_RB well_RB as_IN delivering_VBG on_IN our_PRP$ promise_NN of_IN healthy_JJ returns_NNS to_TO our_PRP$ shareholders_NNS ._.
INNOVATION_NN OUR_NNP COMMERCIALLY_NNP ORIENTATED_NNP RESEARCH_NNP AND_CC DEVELOPMENT_NNP IS_VBZ CONTRIBUTING_NNP TO_TO A_DT STRONG_NNP NEW_NNP PRODUCT_NNP PIPELINE_NNP ._.
TRUST_NNP OUR_NNP SUSTAINABILITY_NNP PROGRESS_NNP HAS_VBZ BEEN_NNP RECOGNISED_NNP BY_IN OUR_NNP ENTRY_NNP INTO_IN THE_DT DOW_NNP JONES_NNP SUSTAINABILITY_NNP INDEX_NNP FOR_IN 2003_CD ._.
Where_WRB this_DT icon_NN appears_VBZ ,_, more_JJR information_NN can_MD be_VB found_VBN at_IN an_DT alternative_JJ source_NN ._.
For_IN more_JJR detailed_JJ financial_JJ information_NN visit_NN www_NN ._.
html_NN TriGen_NNP A_NNP summer_NN time_NN car_NN crash_NN landed_VBD this_DT universitybound_JJ student_NN on_IN a_DT surgeons_NNS operating_VBG table_NN with_IN a_DT femoral_JJ fracture_NN ._.
The_DT less-invasive_JJ TriGen_NNP femoral_JJ nailing_NN system_NN helped_VBD to_TO mend_VB her_PRP$ broken_JJ bone_NN and_CC restored_VBD her_PRP to_TO walking_VBG so_IN she_PRP could_MD start_VB the_DT autumn_NN term_NN in_IN time_NN ._.
We_PRP have_VBP had_VBD another_DT excellent_JJ year_NN of_IN growth_NN within_IN each_DT of_IN our_PRP$ three_CD businesses_NNS ._.
Financial_NNP performance_NN and_CC dividend_NN Chairmans_NNP Group_NNP sales_NNS grew_VBD strongly_RB ,_, led_VBN by_IN the_DT Orthopaedics_NNPS business_NN ._.
Underlying_JJ growth_NN of_IN statement_NN 14_CD %_NN was_VBD augmented_VBN by_IN acquisitions_NNS ,_, which_WDT added_VBD a_DT further_JJ 4_CD %_NN ._.
Our_PRP$ drive_NN to_TO deliver_VB innovative_JJ products_NNS across_IN all_DT our_PRP$ businesses_NNS is_VBZ paying_VBG off_RP In_IN 2002_CD we_PRP achieved_VBD our_PRP$ targets_NNS within_IN the_DT and_CC we_PRP are_VBP also_RB benefiting_VBG from_IN the_DT past_JJ two_CD Orthopaedics_NNPS ,_, Endoscopy_NNP and_CC Advanced_NNP years_NNS sales_NNS force_NN expansions_NNS ._.
Each_DT of_IN Smith_NNP &_CC Nephews_NNP businesses_NNS strengthened_VBD its_PRP$ We_PRP achieved_VBD an_DT ongoing_JJ operating_NN margin_NN positions_NNS in_IN the_DT markets_NNS in_IN which_WDT it_PRP operates_VBZ before_IN exceptional_JJ items_NNS of_IN 16.5_CD %_NN ,_, despite_IN the_DT through_IN a_DT combination_NN of_IN sales_NNS growth_NN ,_, new_JJ dissynergies_NNS of_IN the_DT restructuring_NN divestments_VBZ products_NNS and_CC technology_NN acquisition_NN ._.
The_DT underlying_VBG margin_NN increased_VBN by_IN 0.7_CD %_NN ._.
Before_IN goodwill_NN amortisation_NN ,_, In_IN March_NNP 2002_CD we_PRP acquired_VBD and_CC have_VBP since_IN the_DT margin_NN was_VBD 18.1_CD %_NN ._.
successfully_RB integrated_VBN ORATEC_NNP Interventions_NNPS ,_, Inc._NNP establishing_VBG our_PRP$ Endoscopy_JJ business_NN as_IN Investors_NNS continue_VBP to_TO recognize_VB the_DT companys_NNS a_DT leader_NN in_IN radiofrequency_NN technology_NN and_CC strength_NN and_CC share_NN price_NN growth_NN potential_NN ._.
Smith_NNP minimally_RB invasive_JJ spinal_JJ surgery_NN ._.
We_PRP also_RB &_CC Nephew_NNP was_VBD one_CD of_IN the_DT UKs_NNP best-performing_JJ acquired_VBD the_DT remaining_VBG half_NN of_IN the_DT Dermagraft_NN stocks_NNS in_IN 2002_CD ,_, outperforming_VBG the_DT FTSE_NNP 100_CD by_IN and_CC TransCyte_NNP joint_JJ arrangements_NNS from_IN more_JJR than_IN 20_CD %_NN ._.
The_DT recommended_VBN final_JJ dividend_NN Advanced_NNP Tissue_NNP Sciences_NNPS ,_, Inc._NNP gaining_VBG full_JJ is_VBZ increased_VBN to_TO 3.00_CD p_NN ,_, making_VBG a_DT total_JJ dividend_NN strategic_JJ control_NN of_IN those_DT products_NNS ._.
We_PRP disposed_VBD of_IN our_PRP$ Rehabilitation_NNP business_NN People_NNS to_TO AbilityOne_NNP Corporation_NNP also_RB in_IN March_NNP 2002_CD ,_, Our_PRP$ people_NNS take_VBP pride_NN in_IN our_PRP$ products_NNS which_WDT retaining_VBG a_DT 21.5_CD %_NN interest_NN in_IN the_DT expanded_VBN enable_VBP patients_NNS to_TO regain_VB their_PRP$ lives_NNS ._.
This_DT focused_VBD the_DT group_NN on_IN our_PRP$ three_CD extremely_RB talented_JJ group_NN of_IN individuals_NNS and_CC we_PRP chosen_VBN areas_NNS of_IN expertise_NN ._.
thank_VB them_PRP for_IN their_PRP$ commitment_NN ,_, creativity_NN and_CC energy_NN in_IN serving_VBG the_DT company_NN and_CC the_DT medical_JJ community_NN ._.
02_CD Smith_NNP &_CC Nephew_NNP 2002_CD TriVex_NNP procedure_NN Dermagraft_NNP She_PRP faces_VBZ the_DT same_JJ A_DT keen_JJ golfer_NN ,_, he_PRP has_VBZ problems_NNS every_DT mother_NN suffered_VBD from_IN diabetes_NN does_VBZ :_: dressing_VBG the_DT kids_NNS ,_, all_DT his_PRP$ life_NN ._.
He_PRP ignored_VBD making_VBG lunches_NNS ,_, finding_VBG a_DT wound_NN on_IN his_PRP$ foot_NN ,_, time_NN for_IN herself_PRP ._.
Faced_VBN thinking_VBG it_PRP would_MD clear_VB with_IN an_DT uphill_JJ battle_NN of_IN up_RB ,_, but_CC when_WRB he_PRP lost_VBD another_DT type_NN one_CD sensation_NN in_IN his_PRP$ lower_JJR against_IN unsightly_JJ ,_, painful_JJ leg_NN he_PRP finally_RB went_VBD to_TO see_VB varicose_JJ veins_NNS ,_, she_PRP his_PRP$ doctor_NN ._.
The_DT foot_NN ulcer_NN received_VBD treatment_NN with_IN was_VBD so_RB serious_JJ he_PRP was_VBD the_DT TriVex_NNP procedure_NN ._.
in_IN real_JJ danger_NN of_IN having_VBG She_PRP can_MD now_RB handle_VB the_DT limb_NN amputated_VBD ._.
the_DT challenges_NNS of_IN After_IN 12_CD weeks_NNS of_IN being_VBG motherhood_VBN without_IN the_DT treated_VBN with_IN Dermagraft_NNP ,_, added_VBD difficulty_NN of_IN leg_NN a_DT bio-engineered_JJ human_JJ pain_NN ,_, which_WDT allows_VBZ her_PRP$ dermal_JJ replacement_NN ,_, more_JJR time_NN to_TO concentrate_VB he_PRP was_VBD out_IN of_IN the_DT danger_NN on_IN what_WP matters_VBZ most_RBS zone_NN and_CC looking_VBG forward_RB her_PRP$ family_NN ._.
We_PRP remain_VBP confident_JJ in_IN our_PRP$ ability_NN to_TO deliver_VB sustainable_JJ growth_NN for_IN the_DT future_NN ._.
We_PRP pay_VBP particular_JJ tribute_NN to_TO Larry_NNP Papasan_NNP markets_NNS ._.
In_IN 2003_CD ,_, we_PRP will_MD see_VB the_DT impact_NN of_IN for_IN his_PRP$ valued_VBN contribution_NN as_IN President_NNP of_IN the_DT our_PRP$ strong_JJ ongoing_JJ sales_NNS and_CC profit_NN growth_NN Orthopaedics_NNP business_NN ._.
He_PRP retired_VBD at_IN the_DT end_NN on_IN our_PRP$ reported_VBN results_NNS without_IN the_DT impact_NN of_IN 2002_CD and_CC we_PRP welcome_VBP David_NNP Illingworth_NNP ,_, of_IN divestments_NNS ._.
who_WP has_VBZ joined_VBN us_PRP to_TO lead_VB the_DT division_NN to_TO further_JJ success_NN ._.
We_PRP have_VBP a_DT leading_JJ range_NN of_IN technology_NN and_CC products_NNS that_WDT repair_VBP and_CC heal_VBP the_DT human_JJ body_NN ._.
Board_NNP We_PRP will_MD maintain_VB our_PRP$ progress_NN by_IN investing_VBG in_IN Tim_NNP Lankester_NNP has_VBZ chosen_VBN not_RB to_TO stand_VB again_RB new_JJ and_CC differentiated_JJ technologies_NNS which_WDT bring_VBP for_IN re-election_NN to_TO the_DT Board_NNP and_CC will_MD be_VB standing_VBG benefits_NNS to_TO patients_NNS ,_, and_CC in_IN the_DT specialist_NN sales_NNS down_RB at_IN the_DT AGM_NNP in_IN April_NNP ._.
We_PRP thank_VBP him_PRP for_IN forces_NNS to_TO bring_VB these_DT products_NNS to_TO the_DT medical_JJ his_PRP$ contribution_NN over_IN the_DT last_JJ seven_CD years_NNS ._.
We_PRP will_MD continue_VB to_TO invest_VB in_IN our_PRP$ businesses_NNS by_IN increasing_VBG sales_NNS force_NN strength_NN ,_, Corporate_JJ governance_NN has_VBZ been_VBN a_DT priority_NN adding_VBG manufacturing_NN capacity_NN and_CC enhancing_VBG over_IN the_DT past_JJ year_NN particularly_RB as_IN we_PRP are_VBP listed_VBN new_JJ product_NN development_NN to_TO generate_VB vigorous_JJ on_IN both_DT the_DT London_NNP and_CC New_NNP York_NNP Stock_NNP growth_NN ._.
We_PRP will_MD also_RB acquire_VB businesses_NNS or_CC Exchanges_NNS ._.
Smith_NNP &_CC Nephew_NNP is_VBZ committed_VBN to_TO technologies_NNS that_WDT strengthen_VBP our_PRP$ long_JJ term_NN an_DT open_JJ and_CC constructive_JJ relationship_NN with_IN our_PRP$ prospects_NNS ._.
shareholders_NNS and_CC the_DT overall_JJ investment_NN community_NN ._.
We_PRP are_VBP working_VBG to_TO comply_VB with_IN the_DT We_PRP remain_VBP confident_JJ of_IN delivering_VBG sustainable_JJ new_JJ US_NNP Sarbanes-Oxley_NNP Act_NNP and_CC the_DT ongoing_JJ growth_NN and_CC believe_VB we_PRP are_VBP well_RB placed_VBN to_TO detailed_VBN guidelines_NNS being_VBG supplied_VBN by_IN the_DT achieve_VB our_PRP$ mid-teens_NNS underlying_VBG pre-goodwill_JJ Securities_NNPS and_CC Exchange_NNP Commission_NNP ._.
amortisation_NN EPS_NNP growth_NN target_NN going_VBG forward_RB ._.
Outlook_NNP The_DT markets_NNS on_IN which_WDT we_PRP focus_VBP continue_VB to_TO demonstrate_VB robust_JJ growth_NN ._.
Smith_NNP &_CC Nephew_NNP is_VBZ achieving_VBG sales_NNS growth_NN that_WDT outpaces_VBZ the_DT industry_NN ,_, and_CC is_VBZ demonstrating_VBG its_PRP$ ability_NN to_TO grow_VB share_NN and_CC position_NN within_IN the_DT Orthopaedics_NNP ,_, Dudley_NNP Eustace_NNP Endoscopy_NNP and_CC Advanced_NNP Wound_NNP Management_NNP Chairman_NNP Smith_NNP &_CC Nephew_NNP 2002_CD 03_CD Product_NN markets_NNS %_NN Geographic_JJ markets_NNS %_NN sales_NNS from_IN ongoing_JJ operations_NNS sales_NNS from_IN ongoing_JJ operations_NNS UK_NNP 8_CD %_NN Advanced_NNP wound_VBD Africa_NNP ,_, Asia_NNP &_CC management_NN 30_CD %_NN Australasia_NNP 14_CD %_NN Orthopaedics_NNP 43_CD %_NN Continental_NNP Europe_NNP 22_CD %_NN Endoscopy_NNP 27_CD %_NN America_NNP 56_CD %_NN Our_PRP$ new_JJ products_NNS are_VBP driving_VBG our_PRP$ growth_NN and_CC setting_VBG new_JJ standards_NNS of_IN care_NN ._.
Market_NN growth_NN remains_VBZ buoyant_JJ and_CC Chief_NNP Executives_NNS demographics_NNS and_CC lifestyle_NN trends_NNS remain_VBP positive_JJ ._.
Healthcare_NNP expenditure_NN continues_VBZ to_TO grow_VB in_IN all_DT statement_NN our_PRP$ major_JJ markets_NNS ._.
Technology_NN is_VBZ expanding_VBG the_DT marketplace_NN through_IN the_DT growth_NN of_IN less_JJR invasive_JJ and_CC longer_RBR lasting_JJ surgical_JJ techniques_NNS and_CC Delivering_VBG sustainable_JJ growth_NN implants_NNS ._.
With_IN the_DT introduction_NN of_IN new_JJ orthopaedic_JJ In_IN 2002_CD our_PRP$ markets_NNS grew_VBD strongly_RB and_CC once_RB bearing_VBG materials_NNS ,_, led_VBN by_IN Oxinium_NNP from_IN Smith_NNP &_CC again_RB Smith_NNP &_CC Nephew_NNP outpaced_VBD the_DT industry_NN ._.
Nephew_NN ,_, surgeons_NNS are_VBP increasingly_RB treating_VBG I_PRP am_VBP pleased_JJ to_TO report_VB excellent_JJ growth_NN in_IN our_PRP$ younger_JJR patient_JJ groups_NNS ._.
New_NNP techniques_NNS Orthopaedics_NNP ,_, Endoscopy_NNP and_CC Advanced_NNP Wound_VBD continue_VB to_TO simplify_VB and_CC make_VB procedures_NNS faster_RBR ,_, Management_NNP businesses_NNS ._.
and_CC less_RBR invasive_JJ techniques_NNS in_IN orthopaedics_NNS and_CC endoscopy_JJ are_VBP taking_VBG hold_NN as_IN patients_NNS increasingly_RB We_PRP now_RB have_VBP formidable_JJ teams_NNS in_IN place_NN and_CC drive_NN demand_NN ._.
Technology_NNP advancements_NNS in_IN we_PRP are_VBP focused_VBN on_IN three_CD high-growth_NN markets_NNS ._.
treating_VBG hard-to-heal_JJ wounds_NNS are_VBP driving_VBG strong_JJ We_PRP bring_VBP truly_RB innovative_JJ and_CC differentiating_JJ growth_NN in_IN the_DT active_JJ healing_NN sector_NN of_IN the_DT technologies_NNS that_WDT meet_VBP the_DT needs_NNS of_IN physicians_NNS ,_, advanced_VBD wound_NN management_NN market_NN ._.
We_PRP are_VBP marketing_VBG our_PRP$ products_NNS ever_RB more_RBR effectively_RB We_PRP aim_VBP to_TO raise_VB operating_VBG margins_NNS before_IN through_IN expanded_VBN and_CC specialised_VBN global_JJ goodwill_NN amortisation_NN from_IN 18_CD %_NN in_IN 2002_CD to_TO 21_CD %_NN sales_NNS forces_NNS ._.
in_IN 2005_CD ,_, moving_VBG half_PDT a_DT percentage_NN point_NN closer_RBR to_TO that_DT goal_NN in_IN 2003_CD through_IN improvements_NNS in_IN Our_PRP$ underlying_VBG group_NN sales_NNS increase_NN was_VBD 14_CD %_NN in_IN operational_JJ performance_NN and_CC product_NN mix_NN ._.
Sales_NNS in_IN North_NNP America_NNP grew_VBD 15_CD %_NN and_CC the_DT same_JJ time_NN we_PRP will_MD continue_VB to_TO invest_VB in_IN product_NN region_NN now_RB represents_VBZ some_DT 56_CD %_NN of_IN the_DT groups_NNS innovation_NN ,_, and_CC in_IN growing_VBG our_PRP$ sales_NNS teams_NNS by_IN business_NN ._.
Sales_NNS growth_NN in_IN Europe_NNP was_VBD 12_CD %_NN ,_, at_IN least_JJS 10_CD %_NN a_DT year_NN for_IN the_DT foreseeable_JJ future_NN ._.
reflecting_VBG increased_VBN healthcare_NN spending_NN and_CC ageing_VBG populations_NNS ._.
Sales_NNS in_IN the_DT rest_NN of_IN the_DT world_NN Orthopaedics_NNP grew_VBD 16_CD %_NN ._.
Orthopaedics_NNP sales_NNS rose_VBD by_IN an_DT underlying_JJ 20_CD %_NN and_CC its_PRP$ performance_NN continued_VBD to_TO outpace_VB the_DT market_NN ._.
Reconstructive_JJ implant_VBP sales_NNS grew_VBD by_IN an_DT impressive_JJ 20_CD %_NN ,_, boosted_VBN by_IN continued_JJ 04_CD Smith_NNP &_CC Nephew_NNP 2002_CD Oxinium_NNP knee_NN implants_VBZ ElectroBlade_NNP Resector_NNP His_PRP$ dream_NN of_IN early_JJ From_IN twenty_CD years_NNS retirement_NN and_CC new_JJ life_NN experience_NN as_IN an_DT of_IN golf_NN and_CC sailing_NN went_VBD aerobics_NNS instructor_NN ,_, on_IN hold_NN as_IN osteoarthritis_NNS she_PRP understands_VBZ the_DT crippled_VBN his_PRP$ plans_NNS ._.
importance_NN of_IN fitness_NN in_IN Frustrated_NNP by_IN increasing_VBG a_DT well-balanced_JJ lifestyle_NN ._.
pain_NN and_CC lack_NN of_IN mobility_NN ,_, Thats_NNP why_WRB ,_, when_WRB she_PRP he_PRP consulted_VBD his_PRP$ surgeon_NN suffered_VBD a_DT torn_VBN ligament_NN for_IN a_DT solution_NN ._.
Thanks_NNS in_IN her_PRP$ right_JJ knee_NN a_DT year_NN to_TO bilateral_JJ Oxinium_NNP ago_RB ,_, she_PRP wasted_VBD no_DT time_NN knee_NN implants_NNS ,_, this_DT agreeing_VBG to_TO her_PRP$ doctors_NNS retired_VBN banker_NN is_VBZ back_RB recommendation_NN for_IN on_IN course_NN ._.
Due_JJ to_TO reduced_VBN pain_NN and_CC recovery_NN time_NN ,_, she_PRP was_VBD back_RB at_IN the_DT gym_NN soon_RB after_IN the_DT procedure_NN and_CC enjoying_VBG the_DT benefits_NNS of_IN a_DT healthy_JJ lifestyle_NN ._.
Our_PRP$ operational_JJ performance_NN and_CC product_NN mix_NN is_VBZ constantly_RB being_VBG refined_VBN to_TO improve_VB margins_NNS ._.
surgeon_NN response_NN to_TO the_DT additional_JJ Oxinium_NNP will_MD have_VB responsibility_NN for_IN developing_VBG global_JJ knee_NN products_NNS launched_VBN in_IN 2002_CD ._.
We_PRP once_RB again_RB strategy_NN and_CC its_PRP$ own_JJ product_NN development_NN ,_, recorded_VBN industry-leading_JJ growth_NN in_IN this_DT sector_NN ,_, marketing_NN and_CC sales_NNS functions_NNS ._.
They_PRP will_MD share_VB led_VBN by_IN knee_NN growth_NN of_IN 33_CD %_NN ,_, 10_CD %_NN of_IN which_WDT was_VBD common_JJ manufacturing_NN and_CC support_NN contributed_VBN by_IN the_DT introduction_NN of_IN our_PRP$ joint_JJ fluid_NN organizations_NNS ._.
The_DT sales_NNS forces_NNS in_IN major_JJ therapy_NN product_NN ,_, Supartz_NNP ._.
Hip_NN sales_NNS grew_VBD by_IN US_NNP cities_NNS will_MD be_VB specialised_VBN into_IN separate_JJ 17_CD %_NN led_VBN by_IN continued_JJ growth_NN in_IN revision_NN reconstructive_NN and_CC trauma_NN units_NNS on_IN a_DT phased_VBN procedures_NNS ,_, increased_VBD penetration_NN of_IN our_PRP$ highly_RB basis_NN beginning_NN in_IN the_DT first_JJ quarter_NN of_IN 2003_CD ._.
cross_NN linked_VBD polyethylene_NN liners_NNS and_CC continued_VBD strength_NN in_IN our_PRP$ platform_NN hip_NN systems_NNS including_VBG Endoscopy_NNP Synergy_NNP and_CC Echelon_NNP ._.
Endoscopy_JJ sales_NNS grew_VBD at_IN an_DT underlying_VBG 10_CD %_NN Sales_NNS pricing_VBG in_IN Orthopaedics_NNP remained_VBD positive_JJ with_IN strong_JJ growth_NN coming_VBG from_IN outside_IN the_DT US_NNP ._.
The_DT company_NN acquired_VBD the_DT ORATEC_NNP minimally_RB invasive_JJ joint_JJ and_CC spine_NN business_NN in_IN the_DT year_NN ,_, The_DT Oxinium_NNP knee_NN has_VBZ been_VBN an_DT outstanding_JJ which_WDT added_VBD 9_CD %_NN to_TO sales_NNS growth_NN and_CC has_VBZ given_VBN success_NN since_IN its_PRP$ launch_NN in_IN 2001_CD ._.
We_PRP have_VBP us_PRP a_DT leading_VBG position_NN in_IN radio_NN frequency_NN continued_VBD to_TO invest_VB in_IN the_DT Oxinium_NNP program_NN technology_NN in_IN arthroscopy_JJ ._.
and_CC Computer_NNP Assisted_NNP Surgery_NNP throughout_IN the_DT year_NN where_WRB we_PRP have_VBP received_VBN US_NNP regulatory_JJ Knee_NN and_CC shoulder_NN ligament_NN repair_NN products_NNS approval_NN for_IN hip_NN ,_, knee_NN and_CC trauma_NN applications_NNS ._.
grew_VBD particularly_RB strongly_RB at_IN 21_CD %_NN making_VBG the_DT We_PRP have_VBP developed_VBN an_DT Oxinium_NNP femoral_JJ head_NN group_NN the_DT market_NN leader_NN in_IN arthroscopic_JJ repair_NN ._.
for_IN hips_NNS and_CC have_VBP already_RB launched_VBN the_DT product_NN New_NNP repair_NN products_NNS were_VBD launched_VBN during_IN the_DT in_IN 2003_CD ._.
year_NN to_TO strengthen_VB our_PRP$ position_NN in_IN the_DT arthroscopy_JJ market_NN ,_, including_VBG TwinFix_NNP ,_, a_DT specialised_JJ shoulder_NN We_PRP are_VBP creating_VBG two_CD divisions_NNS within_IN our_PRP$ repair_NN device_NN ._.
New_NNP bioresorbable_JJ screws_NNS for_IN orthopaedic_JJ business_NN ,_, Reconstruction_NN and_CC ligament_NN fixation_NN performed_VBD well_RB ._.
This_DT initiative_NN is_VBZ aimed_VBN at_IN sustaining_VBG has_VBZ brought_VBN us_PRP a_DT unique_JJ product_NN that_WDT combines_VBZ our_PRP$ industry_NN leading_VBG performance_NN by_IN improving_VBG simultaneous_JJ resection_NN with_IN coagulation_NN of_IN soft_JJ the_DT focus_NN on_IN these_DT separate_JJ market_NN sectors_NNS ._.
We_PRP also_RB introduced_VBD a_DT bipolar_NN cutting_VBG This_DT structure_NN will_MD enable_VB us_PRP to_TO bring_VB technology_NN and_CC ablation_NN system_NN for_IN the_DT Vulcan_NNP generator_NN to_TO market_NN faster_RBR and_CC increase_VB our_PRP$ customer_NN responsiveness_NN and_CC satisfaction_NN ._.
Each_DT division_NN Smith_NNP &_CC Nephew_NNP 2002_CD 05_CD Business_NN overview_NN Served_VBN markets_NNS and_CC Business_NN growth_NN in_IN 2002_CD overview_VBD World_NNP market_NN value_NN Orthopaedics_NNP Growth_NNP :_: 13_CD %_NN A_DT comprehensive_JJ highly_RB advanced_JJ range_NN of_IN orthopaedic_JJ implant_VB and_CC trauma_VB products_NNS ._.
5.2_CD bn_NN Implants_NNS for_IN hips_NNS ,_, knees_NNS and_CC shoulders_NNS Trauma_NNP products_NNS for_IN severely_RB broken_VBN bones_NNS utilising_VBG internal_JJ and_CC external_JJ fixation_NN methods_NNS Clinical_JJ therapies_NNS including_VBG ultrasound_NN bone_NN healing_VBG Market_NN position_NN devices_NNS and_CC joint_JJ fluid_NN therapy_NN 6th_JJ We_PRP have_VBP a_DT unique_JJ range_NN of_IN technology_NN and_CC products_NNS which_WDT repair_VBP the_DT human_JJ body_NN ._.
We_PRP are_VBP World_NNP market_NN value_NN Endoscopy_NNP Growth_NNP :_: 6_CD %_NN Industry_NN leader_NN in_IN the_DT development_NN and_CC commercialisation_NN of_IN endoscopic_JJ minimally_RB invasive_JJ surgery_NN products_NNS and_CC techniques_NNS ._.
3.0_CD bn_NN Access_NNP Fluid_NNP management_NN and_CC insufflation_NN instruments_NNS IDET_NNP procedure_NN for_IN better_JJR surgical_JJ access_NN ._.
After_IN years_NNS of_IN struggling_VBG Visualisation_NNP Digital_NNP cameras_NNS ,_, digital_JJ image_NN capture_NN ,_, Market_NNP position_NN arthroscopy_NN with_IN lower_JJR back_RB pain_NN central_JJ control_NN ,_, multimedia_NNS broadcasting_VBG ,_, scopes_NNS ,_, resulting_VBG from_IN a_DT herniated_VBN light_JJ sources_NNS and_CC monitors_NNS to_TO assist_VB with_IN visualisation_NN ._.
disc_NN ,_, he_PRP was_VBD able_JJ to_TO use_VB Resection_NNP State-of-the-art_JJ radiofrequency_NN wands_NNS ,_, 1st_CD his_PRP$ landscaping_NN skills_NNS ElectroMechanical_NNP and_CC mechanical_JJ blades_NNS ,_, and_CC hand_NN once_RB again_RB after_IN being_VBG instruments_NNS for_IN resecting_VBG tissue_NN ._.
treated_VBN with_IN Intradiscal_NNP Repair_NNP Specialised_NNP devices_NNS ,_, fixation_NN systems_NNS and_CC ElectroThermal_NNP Therapy_NNP bioabsorbable_JJ materials_NNS to_TO repair_VB damaged_JJ tissue_NN ._.
also_RB known_VBN as_IN the_DT IDET_NNP procedure_NN ._.
World_NNP market_NN value_NN Advanced_NNP Wound_NNP Management_NNP Growth_NNP :_: 12_CD %_NN Advanced_NNP treatment_NN for_IN hard-to-heal_JJ wounds_NNS offering_VBG a_DT complete_JJ range_NN of_IN products_NNS from_IN initial_JJ wound_NN bed_NN preparation_NN through_IN to_TO successful_JJ wound_NN closure_NN ._.
1.5_CD bn_NN These_DT products_NNS are_VBP targeted_VBN particularly_RB at_IN wounds_NNS connected_VBN with_IN the_DT elderly_JJ ._.
Pressure_NN ulcers_NNS Market_NN position_NN Venous_NNP leg_NN ulcers_NNS Diabetic_NNP foot_NN ulcers_NNS Serious_JJ burns_NNS 1st_CD For_IN more_JJR detailed_JJ business_NN and_CC product_NN information_NN visit_NN :_: www_NN ._.
com_NN businesses_NNS 06_CD Smith_NNP &_CC Nephew_NNP 2002_CD What_WP is_VBZ driving_VBG Our_PRP$ achievements_NNS Our_PRP$ key_JJ new_JJ products_NNS market_NN growth_NN in_IN 2002_CD and_CC developments_NNS in_IN 2002_CD Ilizarov_NNP technique_NN Both_DT legs_NNS had_VBD been_VBN deformed_VBN since_IN birth_NN ,_, but_CC on_IN September_NNP 11_CD ,_, 2001_CD ,_, she_PRP walked_VBD down_RP nearly_RB Expanding_VBG patient_JJ pool_NN Grew_VBD sales_NNS 20_CD %_NN Continued_VBN rollout_NN 50_CD flights_NNS of_IN World_NNP Trade_NNP Increasing_VBG numbers_NNS of_IN Expanded_JJ global_JJ sales_NNS of_IN Oxinium_NNP knee_NN Center_NNP stairs_NNS to_TO safety_NN ._.
elderly_JJ people_NNS living_VBG longer_RBR team_NN by_IN 12_CD %_NN applications_NNS A_DT surgeon_NN had_VBD corrected_VBN Expectation_NN of_IN better_JJR Over_IN 10,000_CD Oxinium_NNP Accuris_NNP minimally_RB invasive_JJ her_PRP$ limbs_NNS using_VBG the_DT Ilizarov_NNP quality_NN of_IN life_NN knee_NN implants_VBZ uni-compartmental_JJ knee_NN technique_NN ._.
New_NNP ,_, longer-lasting_JJ Over_IN 250_CD Computer_NN instrumentation_NN materials_NNS technology_NN Assisted_VBN total_JJ knee_NN Exogen_NNP 3000_CD Demand_NN for_IN less_JJR invasive_JJ procedures_NNS newly_RB OrthoGuard_NNP AB_NNP procedures_NNS branded_VBD as_IN Achieve_NNP antimicrobial_JJ sleeve_NN ,_, Patient_NNP knowledge_NN due_JJ Supartz_NNP joint_JJ fluid_NN the_DT orthopaedic_NN to_TO the_DT internet_NN and_CC media_NNS treatment_NN exceeding_VBG industrys_NNS first_RB coated_JJ medical_JJ device_NN Completed_VBN new_JJ to_TO be_VB cleared_VBN by_IN the_DT US_NNP manufacturing_NN facility_NN regulatory_JJ agency_NN focusing_VBG on_IN three_CD research_NN areas_NNS non-invasive_JJ stimulation_NN ,_, tissue_NN engineering_NN ,_, bioabsorbables_NNS ._.
Increase_VB in_IN sports_NNS injuries_NNS Grew_VBD sales_NNS 10_CD %_NN TwinFix_NNP bioabsorbable_JJ More_RBR active_JJ lifestyles_NNS Entry_NNP into_IN the_DT minimally_RB suture_JJ anchor_VBP for_IN Increased_VBN surgeon_NN use_NN invasive_JJ spinal_JJ market_NN shoulder_NN repair_NN of_IN endoscopic_JJ techniques_NNS through_IN ORATEC_NNP ElectroBlade_NNP Resector_NNP Innovative_JJ technological_JJ acquisition_NN Vulcan_NNP System_NNP RF_NNP developments_NNS Launch_VBP of_IN the_DT Digital_NNP generator_NN Need_VBD for_IN cost-effective_JJ Operating_NN Room_NN concept_NN Vision_NNP 337_CD Autoclavable_JJ procedures_NNS in_IN hospitals_NNS Major_JJ growth_NN in_IN implants_NNS Camera_NNP System_NNP Growing_VBG demand_NN for_IN for_IN soft_JJ tissue_NN repair_NN Decompression_NNP Catheter_NNP digitally-integrated_VBD Launched_VBN industrys_NNS first_RB for_IN herniated_VBN discs_NNS OR_NNP equipment_NN ElectroMechanical_NNP Saphyre_NNP bipolar_NN ablation_NN Growth_NN in_IN ambulatory_JJ resection_NN device_NN probe_NN ProGuide_NNP surgery_NN centres_VBZ Reached_VBN 30,000_CD Having_VBG developed_VBN Payer_NN support_NN driven_VBN procedures_NNS for_IN TriVex_NNP a_DT venous_JJ leg_NN ulcer_NN ,_, by_IN supporting_VBG clinical_JJ Launched_VBN worldwide_NN nurses_NNS at_IN his_PRP$ local_JJ evidence_NN network_NN of_IN surgeon_NN hospital_NN agreed_VBD to_TO take_VB training_NN sites_NNS part_NN in_IN the_DT clinical_JJ trial_NN of_IN ProGuide_NNP ,_, a_DT two-layer_JJ elastic_JJ compression_NN More_JJR elderly_JJ people_NNS Grew_VBD sales_NNS 11_CD %_NN Improved_VBN and_CC extended_VBN system_NN designed_VBN for_IN living_VBG longer_JJR World_NNP leadership_NN in_IN Allevyn_NNP range_NN launched_VBD venous_JJ leg_NN ulcers_NNS ._.
This_DT More_JJR clinically_RB advanced_VBN advanced_JJ wound_NN care_NN Continued_VBN global_JJ roll-out_NN allowed_VBD the_DT correct_JJ methods_NNS of_IN healing_VBG wounds_NNS strengthened_VBD of_IN Acticoat_NNP silver_NN burns_NNS pressure_NN to_TO be_VB applied_VBN Therapies_NNS that_WDT reduce_VBP Allevyn_NNP ,_, our_PRP$ largest_JJS dressing_VBG and_CC reduced_VBD the_DT number_NN nursing_NN time_NN and_CC speed_NN product_NN ,_, grew_VBD 21_CD %_NN Global_JJ launch_NN of_IN Cutinova_NNP of_IN dressing_VBG changes_NNS ._.
recovery_NN for_IN cost_NN efficiency_NN Acticoat_NNP burns_NNS dressing_VBG Hydro_NNP and_CC range_NN Two-thirds_NNS of_IN global_JJ market_NN increased_VBD sales_NNS by_IN 65_CD %_NN extension_NN still_RB to_TO be_VB converted_VBN to_TO Successful_JJ launch_NN of_IN Dermagraft_NNP full_JJ US_NNP launch_NN advanced_VBD wound_NN healing_VBG Wound_JJ Bed_NNP Preparation_NNP New_NNP ,_, advanced_VBD concept_NN technologies_NNS expanding_VBG 100_CD %_NN ownership_NN of_IN breadth_NN of_IN market_NN Dermagraft_NNP and_CC TransCyte_NNP 88_CD %_NN coverage_NN of_IN US_NNP outpatient_NN population_NN for_IN Dermagraft_NNP on_IN an_DT underlying_JJ basis_NN Smith_NNP &_CC Nephew_NNP 2002_CD 07_CD Acticoat_NNP Oxinium_NNP hip_NN implant_VBP She_PRP tried_VBD to_TO help_VB her_PRP$ Although_IN he_PRP could_MD have_VB mother_NN with_IN the_DT cooking_NN delayed_VBD his_PRP$ total_JJ hip_NN but_CC she_PRP pulled_VBD a_DT pan_VB of_IN replacement_NN surgery_NN boiling_VBG water_NN off_IN the_DT until_IN after_IN his_PRP$ daughters_NNS stove_VBP ,_, causing_VBG mixed_JJ wedding_NN ,_, Smith_NNP &_CC partial_JJ thickness_NN burns_NNS Nephews_NNP mini-incision_NN to_TO her_PRP$ arms_NNS and_CC upper_JJ technique_NN ,_, in_IN concert_NN torso_NN ._.
In_IN the_DT burns_NNS unit_NN with_IN an_DT Oxinium_NNP implant_VBP ,_, at_IN the_DT hospital_NN ,_, Acticoat_NNP ,_, restored_VBD his_PRP$ pain-free_NN a_DT unique_JJ antimicrobial_JJ mobility_NN in_IN time_NN to_TO give_VB barrier_NN dressing_VBG ,_, was_VBD away_RB the_DT bride_NN and_CC take_VB applied_VBN to_TO the_DT affected_VBN a_DT full_JJ part_NN in_IN this_DT important_JJ areas_NNS ,_, helping_VBG to_TO minimize_VB day_NN in_IN his_PRP$ daughters_NNS life_NN ._.
the_DT risk_NN of_IN infection_NN and_CC scarring_NN ._.
The_DT burns_NNS healed_VBD quickly_RB ,_, allowing_VBG her_PRP to_TO rejoin_VB her_PRP$ playmates_NNS at_IN nursery_NN school_NN ._.
Our_PRP$ commercially_RB orientated_VBN innovation_NN is_VBZ contributing_VBG a_DT strong_JJ new_JJ product_NN pipeline_NN ,_, Sustaining_VBG our_PRP$ growth_NN rate_NN Chief_NNP Executives_NNS Over_IN the_DT past_JJ few_JJ years_NNS we_PRP have_VBP maintained_VBN consistently_RB strong_JJ investment_NN in_IN expanding_VBG the_DT statement_NN continued_VBD sales_NNS force_NN and_CC expanding_VBG our_PRP$ product_NN pipeline_NN ._.
In_IN 2002_CD we_PRP expanded_VBD the_DT Orthopaedics_NNPS sales_NNS and_CC a_DT thermal_JJ decompression_NN catheter_NN for_IN team_NN by_IN 12_CD %_NN ,_, the_DT Endoscopy_NNP team_NN by_IN 30_CD %_NN herniated_VBD spinal_JJ discs_NNS ._.
The_DT Digital_NNP Operating_NN including_VBG the_DT sales_NNS force_NN acquired_VBN with_IN ORATEC_NNP ,_, Room_NNP concept_NN gained_VBD ground_NN with_IN installations_NNS and_CC the_DT Advanced_NNP Wound_NNP Management_NNP team_NN in_IN leading_VBG hospitals_NNS ._.
1_CD Advanced_NNP Wound_NNP Management_NNP We_PRP invested_VBD 5_CD 2_CD %_NN of_IN sales_NNS revenue_NN in_IN research_NN In_IN its_PRP$ first_JJ full_JJ year_NN as_IN an_DT advanced_JJ wound_NN and_CC development_NN across_IN our_PRP$ businesses_NNS ._.
In_IN management_NN business_NN ,_, we_PRP strengthened_VBD our_PRP$ 2002_CD ,_, products_NNS introduced_VBN in_IN the_DT last_JJ three_CD years_NNS world-leading_JJ position_NN in_IN advanced_JJ treatments_NNS rose_VBD to_TO 18_CD %_NN of_IN sales_NNS ._.
Our_PRP$ group_NN focus_NN on_IN unique_JJ for_IN hard-to-heal_JJ wounds_NNS ._.
Underlying_JJ sales_NNS methods_NNS to_TO repair_VB and_CC heal_VB the_DT human_JJ body_NN growth_NN was_VBD 11_CD %_NN ,_, with_IN the_DT Allevyn_NNP product_NN range_NN has_VBZ led_VBN to_TO group_NN wide_JJ research_NN in_IN three_CD fields_NNS :_: achieving_VBG 21_CD %_NN ._.
We_PRP have_VBP successfully_RB integrated_VBN bioresorbable_JJ materials_NNS to_TO facilitate_VB healing_NN and_CC into_IN the_DT business_NN the_DT advanced_JJ wound_NN products_NNS surgical_JJ reconstruction_NN :_: tissue_NN engineering_NN to_TO of_IN Beiersdorf_NNP and_CC the_DT Acticoat_NNP silver_NN product_NN for_IN help_NN replace_VB ,_, repair_VB and_CC regenerate_VB damaged_JJ burns_NNS acquired_VBN in_IN 2001_CD and_CC these_DT products_NNS are_VBP tissue_NN :_: and_CC non-invasive_JJ devices_NNS to_TO stimulate_VB growing_VBG strongly_RB ._.
Towards_IN the_DT end_NN of_IN the_DT year_NN ,_, we_PRP secured_VBD 100_CD %_NN Enhancing_VBG manufacturing_NN capacity_NN and_CC quality_NN ownership_NN of_IN the_DT Dermagraft_NNP and_CC TransCyte_NNP To_TO meet_VB future_JJ sales_NNS growth_NN we_PRP expanded_VBD our_PRP$ arrangement_NN by_IN acquiring_VBG ATSs_NNP 50_CD %_NN share_NN ._.
Orthopaedics_NNS and_CC Endoscopy_JJ manufacturing_NN Reimbursement_NN for_IN Dermagraft_NNP continues_VBZ to_TO capacity_NN ._.
Orthopaedics_NNP enlarged_JJ its_PRP$ production_NN progress_NN well_RB ,_, with_IN 88_CD %_NN of_IN the_DT outpatient_NN space_NN in_IN Memphis_NNP ,_, Tennessee_NNP ,_, by_IN about_IN a_DT third_JJ ._.
population_NN now_RB covered_VBN in_IN the_DT US_NNP ._.
Sales_NNS of_IN Endoscopy_NNP expanded_VBD two_CD factories_NNS and_CC moved_VBD Dermagraft_NNP in_IN its_PRP$ US_NNP launch_NN year_NN achieved_VBD 3m_CD ._.
its_PRP$ headquarters_NN to_TO new_JJ premises_NNS near_IN its_PRP$ production_NN facility_NN in_IN Andover_NNP ,_, Massachusetts_NNP ._.
Advanced_NNP Wound_NNP Management_NNP has_VBZ begun_VBN 08_CD Smith_NNP &_CC Nephew_NNP 2002_CD Allevyn_NNP TwinFix_NNP bioabsorbable_JJ Following_VBG a_DT long_JJ illness_NN ,_, suture_NN anchor_VB she_PRP suffered_VBD from_IN a_DT He_PRP was_VBD a_DT talented_JJ tennis_NN severe_JJ pressure_NN ulcer_NN player_NN in_IN college_NN ,_, and_CC he_PRP around_IN the_DT sacral_JJ area_NN ,_, never_RB lost_VBD his_PRP$ love_NN for_IN the_DT causing_VBG much_JJ pain_NN and_CC sport_NN ._.
After_IN suffering_VBG a_DT discomfort_NN ,_, and_CC limiting_VBG serious_JJ rotator_NN cuff_NN injury_NN ,_, her_PRP$ mobility_NN ._.
Despite_IN the_DT his_PRP$ days_NNS of_IN swinging_VBG a_DT efforts_NNS of_IN a_DT district_NN nurse_NN ,_, racket_NN seemed_VBD to_TO have_VB it_PRP wasnt_VB until_IN Allevyn_NNP vanished_VBD forever_RB ._.
But_CC Sacral_NNP was_VBD used_VBN ,_, a_DT thanks_NNS to_TO the_DT use_NN of_IN shaped_JJ ,_, highly_RB absorbent_JJ a_DT TwinFix_NNP bioabsorbable_JJ hydrocellular_JJ dressing_VBG ,_, suture_NN anchor_VB by_IN his_PRP$ that_IN the_DT ulcer_NN showed_VBD surgeon_NN ,_, he_PRP is_VBZ back_RB on_IN any_DT signs_NNS of_IN improvement_NN ._.
the_DT court_NN twice_RB a_DT week_NN After_IN a_DT few_JJ weeks_NNS the_DT and_CC easing_VBG the_DT stress_NN of_IN pain_NN was_VBD alleviated_VBN ,_, the_DT work_NN with_IN some_DT friendly_JJ pressure_NN ulcer_NN healed_VBD and_CC competition_NN from_IN the_DT mobility_NN was_VBD restored_VBN ._.
and_CC surgeon_NN medical_JJ education_NN programs_NNS are_VBP continuing_VBG to_TO speed_VB product_NN adoption_NN ._.
building_VBG a_DT new_JJ manufacturing_NN plant_NN in_IN Largo_NNP ,_, Our_PRP$ complete_JJ Sustainability_NNP Report_NNP is_VBZ published_VBN Florida_NNP ,_, near_IN its_PRP$ existing_VBG facilities_NNS ._.
We_PRP continue_VBP to_TO maintain_VB rigorous_JJ quality_NN Outlook_NNP assurance_NN and_CC control_NN systems_NNS that_WDT are_VBP subject_JJ We_PRP are_VBP in_IN the_DT next_JJ phase_NN of_IN our_PRP$ companys_NNS to_TO regular_JJ internal_JJ and_CC external_JJ review_NN ._.
We_PRP have_VBP focused_VBN our_PRP$ businesses_NNS product_NN quality_NN very_RB seriously_RB and_CC are_VBP committed_VBN on_IN three_CD high-growth_NN medical_JJ device_NN sectors_NNS ._.
to_TO the_DT highest_JJS standards_NNS of_IN manufacturing_VBG quality_NN ._.
We_PRP are_VBP delivering_VBG sustained_VBN growth_NN in_IN sales_NNS and_CC underlying_VBG operating_VBG margins_NNS ._.
Business_NNP Development_NNP In_IN March_NNP we_PRP completed_VBD our_PRP$ restructuring_NN with_IN We_PRP have_VBP excellent_JJ management_NN teams_NNS in_IN place_NN ,_, the_DT disposal_NN of_IN our_PRP$ Rehabilitation_NNP business_NN to_TO intent_NN on_IN building_NN sales_NNS and_CC market_NN share_NN as_RB well_RB AbilityOne_NNP in_IN the_DT US_NNP ._.
We_PRP received_VBD 71m_CD in_IN cash_NN as_IN improving_VBG the_DT financial_JJ performance_NN of_IN their_PRP$ and_CC retained_VBD a_DT 21.5_CD %_NN interest_NN in_IN the_DT enlarged_JJ businesses_NNS ._.
Our_PRP$ new_JJ products_NNS are_VBP advancing_VBG company_NN to_TO benefit_VB from_IN the_DT substantial_JJ value_NN clinical_JJ performance_NN by_IN benefiting_VBG both_DT patients_NNS that_IN we_PRP believe_VBP will_MD be_VB created_VBN by_IN combining_VBG and_CC healthcare_NN systems_NNS ._.
Our_PRP$ sales_NNS people_NNS the_DT two_CD businesses_NNS ._.
continue_VB to_TO be_VB excited_VBN by_IN our_PRP$ product_NN ranges_NNS and_CC we_PRP have_VBP every_DT reason_NN to_TO expect_VB that_IN our_PRP$ Our_PRP$ joint_JJ venture_NN with_IN Beiersdorf_NNP ,_, BSN_NNP Medical_NNP ,_, markets_NNS will_MD themselves_PRP continue_VB to_TO grow_VB ._.
We_PRP had_VBD a_DT successful_JJ trading_NN year_NN ._.
BSN_NNP and_CC remain_VBP confident_JJ that_IN we_PRP can_MD deliver_VB sustainable_JJ AbilityOne_NNP made_VBD a_DT combined_VBN operating_NN profit_NN growth_NN over_IN the_DT next_JJ three_CD years_NNS ._.
Corporate_JJ social_JJ responsibility_NN We_PRP are_VBP committed_VBN to_TO sustainable_JJ development_NN ,_, reducing_VBG our_PRP$ impact_NN on_IN the_DT environment_NN while_IN contributing_VBG to_TO the_DT quality_NN of_IN life_NN enjoyed_VBN by_IN society_NN at_IN large_JJ ._.
We_PRP support_VBP local_JJ communities_NNS Christopher_NNP ODonnell_NNP around_IN our_PRP$ manufacturing_NN operations_NNS and_CC play_VB Chief_NNP Executive_NNP a_DT substantial_JJ role_NN in_IN professional_JJ education_NN in_IN our_PRP$ clinical_JJ fields_NNS ._.
Smith_NNP &_CC Nephew_NNP 2002_CD 09_CD The_DT Board_NNP Non-executive_JJ directors_NNS Dudley_NNP Eustace_NNP 66_CD Christopher_NNP Peter_NNP Hooley_NNP 56_CD Dr_NNP Pamela_NNP Kirby_NNP 49_CD Members_NNS of_IN the_DT Chairman_NNP ODonnell_NNP 56_CD Finance_NNP Director_NNP Appointed_VBD a_DT director_NN Remuneration_NNP Appointed_VBD Deputy_NNP Chief_NNP Executive_NNP He_PRP joined_VBD the_DT group_NN in_IN March_NNP 2002_CD ._.
Committee_NNP Chairman_NNP in_IN 1999_CD and_CC He_PRP joined_VBD the_DT group_NN and_CC was_VBD appointed_VBN She_PRP is_VBZ Chief_NNP Executive_NNP Members_NNP of_IN the_DT Chairman_NNP in_IN January_NNP in_IN 1988_CD and_CC was_VBD a_DT director_NN in_IN 1991_CD ._.
Officer_NNP of_IN Quintiles_NNP Audit_NNP Committee_NNP 2000_CD ._.
He_PRP is_VBZ Chairman_NNP appointed_VBN a_DT director_NN He_PRP is_VBZ a_DT non-executive_JJ Transnational_JJ Members_NNS of_IN the_DT of_IN the_DT Nominations_NNS in_IN 1992_CD ._.
He_PRP was_VBD director_NN of_IN Cobham_NNP plc._NN ._.
Nominations_NNP Committee_NNP ,_, nonappointed_JJ Chief_NNP Committee_NNP executive_NN Chairman_NNP Executive_NNP in_IN 1997_CD ._.
of_IN Sendo_NNP Holdings_NNP plc_NN He_PRP is_VBZ a_DT non-executive_JJ Kenneth_NNP Kemp_NNP is_VBZ and_CC a_DT non-executive_JJ director_NN of_IN BOC_NNP Group_NNP ._.
director_NN of_IN KLM_NNP Royal_NNP Dutch_NNP Airlines_NNPS NV_NNP ,_, Aegon_NNP NV_NNP ,_, Hagemeyer_NNP NV_NNP ,_, Royal_NNP KPN_NNP NV_NNP and_CC Sonae_NNP ._.
We_PRP feel_VBP that_IN our_PRP$ innovative_JJ and_CC responsive_JJ company_NN is_VBZ in_IN a_DT good_JJ position_NN for_IN future_JJ growth_NN ,_, Dr_NNP Alan_NNP Suggett_NNP 59_CD Group_NNP Director_NNP of_IN Group_NNP Technology_NNP He_PRP joined_VBD the_DT group_NN in_IN 1982_CD and_CC was_VBD Executive_NNP appointed_VBN to_TO the_DT Group_NNP Executive_NNP Committee_NNP in_IN Committee_NNP 1986_CD ._.
David_NNP Illingworth_NNP 49_CD President_NNP Orthopaedics_NNP Christopher_NNP ODonnell_NNP ,_, He_PRP joined_VBD the_DT group_NN and_CC Chief_NNP Executive_NNP was_VBD appointed_VBN to_TO the_DT Group_NNP See_VB above_RB ._.
Peter_NNP Hooley_NNP ,_, Finance_NNP Director_NNP See_VB above_RB ._.
Peter_NNP Huntley_NNP 42_CD Jim_NNP Taylor_NNP 46_CD Group_NNP Director_NNP Strategy_NNP Group_NNP Director_NNP Indirect_NNP and_CC Business_NNP Development_NNP Markets_NNP He_PRP joined_VBD the_DT He_PRP joined_VBD the_DT group_NN and_CC group_NN and_CC was_VBD appointed_VBN was_VBD appointed_VBN to_TO the_DT Group_NNP to_TO the_DT Group_NNP Executive_NNP Executive_NNP Committee_NNP Committee_NNP in_IN 2000_CD ._.
in_IN 1998_CD ._.
10_CD Smith_NNP &_CC Nephew_NNP 2002_CD Warren_NNP Knowlton_NNP 56_CD Brian_NNP Larcombe_NNP 49_CD Richard_NNP fide_NNP Schutter_NNP Dr_NNP Rolf_NNP Stomberg_NNP 62_CD Sir_NNP Timothy_NNP Lankester_NNP Appointed_VBD a_DT director_NN Appointed_VBN a_DT director_NN 62_CD Appointed_VBN a_DT A_DT director_NN since_IN 1998_CD ._.
60_CD A_DT director_NN since_IN in_IN November_NNP 2000_CD ._.
in_IN March_NNP 2002_CD ._.
He_PRP director_NN in_IN January_NNP Senior_JJ independent_JJ June_NNP 1996_CD ._.
He_PRP is_VBZ He_PRP is_VBZ Chairman_NNP of_IN the_DT is_VBZ Chief_NNP Executive_NNP of_IN 2001_CD ._.
He_PRP is_VBZ a_DT nondirector_NN and_CC Chairman_NNP president_NN of_IN Corpus_NNP Audit_NNP Committee_NNP and_CC 3i_NNP Group_NNP Plc._NNP ._.
executive_JJ director_NN of_IN the_DT Remuneration_NNP Christi_NNP College_NNP ,_, Oxford_NNP ._.
Group_NNP Chief_NNP Executive_NNP of_IN Varian_NNP Inc._NNP ._.
ING_NNP Committee_NNP ._.
He_PRP is_VBZ Also_RB an_DT independent_JJ of_IN Morgan_NNP Crucible_NNP plc._NN ._.
Americas_NNP ,_, Incyte_NNP Chairman_NNP of_IN director_NN of_IN the_DT London_NNP Genomics_NNPS ,_, MedPointe_NNP Management_NNP Metal_NNP Exchange_NNP and_CC Pharmaceuticals_NNP and_CC Consulting_NNP Group_NNP PLC_NNP Deputy_NNP Chairman_NNP of_IN General_NNP Binding_NNP and_CC a_DT non-executive_JJ the_DT British_JJ Council_NNP ._.
director_NN of_IN Scania_NNP AB_NNP ,_, Stinnes_NNP AG_NNP ,_, Reed_NNP Elsevier_NNP plc_NN ,_, Cordiant_NNP Communications_NNPS plc_NN ,_, Deutsche_NNP BP_NNP AG_NNP ,_, TPG_NNP Group_NNP and_CC Hoyer_NNP GmbH_NNP ._.
with_IN 7,500_CD employees_NNS who_WP commit_VBP their_PRP$ energy_NN and_CC expertise_NN to_TO its_PRP$ continual_JJ improvement_NN ._.
Paul_NNP Williams_NNP 56_CD Jim_NNP Ralston_NNP 56_CD Group_NNP Director_NNP Human_NNP Chief_NNP Legal_NNP Officer_NNP Resources_NNPS He_PRP joined_VBD the_DT He_PRP joined_VBD the_DT group_NN in_IN 1999_CD group_NN and_CC was_VBD appointed_VBN and_CC was_VBD appointed_VBN to_TO the_DT to_TO the_DT Group_NNP Executive_NNP Group_NNP Executive_NNP Committee_NNP Committee_NNP in_IN 1998_CD ._.
in_IN 2002_CD ._.
Jim_NNP Dick_NNP 50_CD Ron_NNP Sparks_VBZ 47_CD President_NNP Wound_NNP President_NNP Endoscopy_NNP Management_NNP He_PRP joined_VBD He_PRP joined_VBD the_DT group_NN in_IN the_DT group_NN in_IN 1977_CD and_CC was_VBD 1983_CD and_CC was_VBD appointed_VBN appointed_VBN to_TO the_DT Group_NNP to_TO the_DT Group_NNP Executive_NNP Executive_NNP Committee_NNP Committee_NNP in_IN 1999_CD ._.
in_IN 1999_CD ._.
Smith_NNP &_CC Nephew_NNP 2002_CD 11_CD Corporate_JJ social_JJ responsibility_NN We_PRP aim_VBP to_TO make_VB our_PRP$ values_NNS of_IN Performance_NNP ,_, Innovation_NNP More_RBR detail_NN on_IN our_PRP$ policies_NNS and_CC the_DT work_NN which_WDT we_PRP and_CC Trust_NNP integral_JJ to_TO the_DT way_NN we_PRP operate_VBP ,_, and_CC are_VBP do_VB in_IN these_DT areas_NNS is_VBZ provided_VBN in_IN the_DT following_VBG text_NN ._.
committed_VBN to_TO the_DT principles_NNS of_IN sustainable_JJ development_NN ._.
This_DT was_VBD recognized_VBN by_IN our_PRP$ admission_NN in_IN 2002_CD on_IN our_PRP$ Environmental_JJ management_NN first_RB application_NN to_TO the_DT Dow_NNP Jones_NNP Sustainability_NNP Index_NNP ._.
We_PRP are_VBP committed_VBN to_TO continuing_VBG reduction_NN in_IN our_PRP$ This_DT is_VBZ the_DT most_RBS widely_RB recognized_VBN arbiter_NN of_IN good_JJ practice_NN environmental_JJ impact_NN :_: we_PRP use_VBP renewable_JJ resources_NNS and_CC we_PRP achieved_VBD the_DT highest_JJS rating_NN in_IN our_PRP$ business_NN sector_NN ._.
wherever_WRB possible_JJ and_CC reduce_VB any_DT adverse_JJ effect_NN from_IN products_NNS and_CC processes_VBZ to_TO a_DT practical_JJ minimum_NN ._.
Our_PRP$ We_PRP published_VBD our_PRP$ second_JJ Sustainability_NNP Report_NNP in_IN April_NNP business_NN units_NNS must_MD take_VB effective_JJ action_NN to_TO control_VB risks_NNS 2002_CD ,_, outlining_VBG our_PRP$ progress_NN in_IN corporate_JJ social_JJ responsibility_NN and_CC minimize_VB environmental_JJ impacts_NNS through_IN systems_NNS CSR_NNP ._.
It_PRP was_VBD more_RBR detailed_JJ and_CC wider_JJR in_IN scope_NN than_IN the_DT and_CC procedures_NNS based_VBN on_IN a_DT thorough_JJ understanding_NN first_RB ,_, with_IN increased_VBN measurement_NN data_NNS and_CC information_NN of_IN the_DT risks_NNS and_CC provision_NN of_IN appropriate_JJ training_NN and_CC on_IN our_PRP$ activities_NNS ._.
Progress_NNP is_VBZ reviewed_VBN annually_RB by_IN the_DT Board_NNP ._.
The_DT third_JJ Sustainability_NNP Report_NNP will_MD be_VB published_VBN on_IN our_PRP$ Over_IN the_DT past_JJ 10_CD years_NNS our_PRP$ environmental_JJ management_NN website_NN in_IN April_NNP and_CC will_MD include_VB new_JJ measurement_NN systems_NNS have_VBP delivered_VBN cost_NN savings_NNS as_RB well_RB as_IN initiatives_NNS ,_, especially_RB in_IN the_DT social_JJ area_NN ._.
At_IN the_DT same_JJ time_NN environmental_JJ benefits_NNS ._.
Our_PRP$ manufacturing_NN processes_VBZ we_PRP will_MD be_VB publishing_VBG a_DT new_JJ Code_NNP of_IN Business_NNP Principles_NNPS are_VBP relatively_RB low_JJ in_IN environmental_JJ impact_NN with_IN locations_NNS in_IN which_WDT brings_VBZ together_RB policies_NNS that_WDT currently_RB appear_VBP in_IN the_DT US_NNP ,_, UK_NNP and_CC Germany_NNP ._.
Our_PRP$ main_JJ environmental_JJ impact_NN different_JJ sections_NNS of_IN our_PRP$ website_NN ,_, updated_VBN and_CC broadened_VBN comes_VBZ from_IN waste_NN generated_VBD at_IN manufacturing_VBG sites_NNS ._.
We_PRP have_VBP included_VBN purchasing_VBG policies_NNS with_IN We_PRP operate_VBP waste_NN prevention_NN and_CC minimisation_NN programs_NNS particular_JJ emphasis_NN on_IN human_JJ rights_NNS and_CC suppliers_NNS throughout_IN the_DT group_NN and_CC are_VBP examining_VBG ways_NNS of_IN assessing_VBG practices_NNS on_IN health_NN ,_, safety_NN and_CC environmental_JJ standards_NNS ._.
sustainable_JJ development_NN aspects_NNS of_IN our_PRP$ products_NNS ._.
In_IN the_DT Through_IN this_DT code_NN we_PRP ensure_VBP that_IN our_PRP$ planning_NN and_CC past_JJ year_NN we_PRP have_VBP focused_VBN on_IN reducing_VBG waste_NN ,_, the_DT business_NN decisions_NNS take_VBP account_NN of_IN ethical_JJ ,_, social_JJ ,_, legal_JJ improvement_NN in_IN recycling_VBG made_VBN in_IN 2001_CD has_VBZ been_VBN sustained_VBN and_CC financial_JJ considerations_NNS ,_, thereby_RB minimizing_VBG risks_NNS and_CC emissions_NNS are_VBP down_RB 12_CD %_NN ._.
This_DT is_VBZ a_DT significant_JJ and_CC balancing_VBG the_DT interests_NNS of_IN all_DT our_PRP$ stakeholders_NNS ._.
achievement_NN considering_VBG the_DT manufacturing_NN expansion_NN which_WDT took_VBD place_NN during_IN the_DT year_NN ._.
Our_PRP$ sustainability_NN efforts_NNS focus_VB on_IN :_: Social_NNP responsibility_NN Environmental_NNP management_NN Employees_NNS Our_PRP$ business_NN units_NNS are_VBP required_VBN to_TO provide_VB safe_JJ Minimising_VBG the_DT impact_NN of_IN our_PRP$ activities_NNS on_IN the_DT environment_NN working_NN conditions_NNS ,_, plant_NN and_CC equipment_NN at_IN all_DT their_PRP$ facilities_NNS ._.
particularly_RB regarding_VBG energy_NN and_CC water_NN use_NN ,_, waste_NN ,_, We_PRP maintain_VBP high_JJ standards_NNS and_CC are_VBP determined_VBN to_TO raise_VB emissions_NNS and_CC discharges_NNS ._.
them_PRP even_RB higher_RBR through_IN sharing_VBG best_JJS practice_NN ._.
Business_NNP unit_NN plans_VBZ include_VBP measures_NNS to_TO improve_VB performance_NN Social_NNP responsibility_NN monitoring_NN ,_, enhance_VB hazard_NN analysis_NN and_CC risk_NN assessment_NN ,_, Employees_NNS Maintaining_VBG high_JJ standards_NNS of_IN health_NN and_CC safety_NN :_: refine_VB emergency_NN plans_NNS and_CC business_NN continuity_NN plans_NNS and_CC providing_VBG training_NN and_CC development_NN :_: giving_VBG people_NNS the_DT deliver_VBP better_JJR targeted_JJ training_NN ._.
opportunity_NN to_TO let_VB us_PRP know_VB how_WRB they_PRP feel_VBP about_IN working_VBG for_IN Smith_NNP &_CC Nephew_NNP and_CC acting_VBG on_IN what_WP they_PRP tell_VBP us_PRP ._.
Our_PRP$ employment_NN policies_NNS emphasise_VBP equality_NN of_IN opportunity_NN ,_, continuous_JJ training_NN and_CC development_NN ,_, open_JJ communications_NNS ,_, Community_NNP Investing_VBG in_IN and_CC working_VBG with_IN the_DT communities_NNS and_CC rewards_NNS appropriate_JJ to_TO local_JJ markets_NNS ._.
Vacancies_NNS are_VBP in_IN which_WDT we_PRP operate_VBP ._.
filled_VBN within_IN the_DT company_NN wherever_WRB possible_JJ ._.
We_PRP treat_VBP employees_NNS with_IN dignity_NN and_CC fairness_NN and_CC have_VBP policies_NNS and_CC Customers_NNS Educating_VBG healthcare_NN professionals_NNS in_IN the_DT procedures_NNS to_TO encourage_VB this_DT culture_NN ._.
We_PRP welcome_VBP disabled_JJ techniques_NNS related_VBN to_TO our_PRP$ product_NN ranges_NNS and_CC providing_VBG people_NNS and_CC make_VB every_DT effort_NN to_TO retain_VB any_DT employee_NN who_WP opportunities_NNS for_IN their_PRP$ continuing_VBG professional_JJ development_NN ._.
Our_PRP$ new_JJ Code_NNP of_IN Business_NNP Principles_NNPS underpins_VBZ the_DT high_JJ standards_NNS we_PRP expect_VBP from_IN our_PRP$ people_NNS ._.
Suppliers_NNS Working_VBG in_IN partnership_NN with_IN suppliers_NNS and_CC fostering_VBG open_JJ ,_, ethical_JJ relationships_NNS with_IN them_PRP ._.
We_PRP recognize_VBP the_DT importance_NN of_IN good_JJ employee_NN communications_NNS ._.
This_DT year_NN we_PRP have_VBP greatly_RB improved_VBN Economic_JJ impact_NN groupwide_NN measurement_NN and_CC data_NNS collection_NN systems_NNS to_TO Making_VBG a_DT positive_JJ contribution_NN to_TO society_NN through_IN creating_VBG monitor_NN such_JJ areas_NNS as_IN employee_NN satisfaction_NN ,_, performance_NN shareholder_NN value_NN ,_, paying_VBG taxes_NNS ,_, investing_VBG capital_NN and_CC appraisal_NN ,_, development_NN and_CC career_NN progression_NN ._.
We_PRP have_VBP creating_VBG employment_NN :_: maximizing_VBG the_DT economic_JJ benefits_NNS also_RB set_VBD up_RP a_DT reporting_NN system_NN to_TO collect_VB data_NNS on_IN training_NN of_IN our_PRP$ products_NNS for_IN healthcare_NN providers_NNS ,_, patients_NNS and_CC throughout_IN the_DT group_NN ._.
These_DT measures_NNS will_MD monitor_VB progress_NN those_DT who_WP pay_VBP the_DT costs_NNS ._.
in_IN the_DT coming_VBG years_NNS and_CC help_VB ensure_VB that_IN we_PRP target_VBP our_PRP$ efforts_NNS in_IN the_DT most_RBS effective_JJ manner_NN ._.
More_JJR information_NN is_VBZ available_JJ on_IN our_PRP$ website_NN at_IN :_: 12_CD Smith_NNP &_CC Nephew_NNP 2002_CD www_NN ._.
com_NN sustainability2002_NN In_IN 2002_CD we_PRP conducted_VBD our_PRP$ second_JJ global_JJ opinion_NN survey_NN Suppliers_NNS We_PRP treat_VBP suppliers_NNS with_IN dignity_NN and_CC fairness_NN ,_, and_CC communicated_VBD the_DT results_NNS to_TO staff_NN worldwide_NN ._.
Once_RB and_CC expect_VB them_PRP to_TO do_VB the_DT same_JJ with_IN their_PRP$ own_JJ employees_NNS again_RB we_PRP had_VBD over_IN 80_CD %_NN of_IN employees_NNS participating_VBG in_IN the_DT and_CC suppliers_NNS ._.
Our_PRP$ Code_NNP of_IN Business_NNP Principles_NNPS makes_VBZ clear_JJ survey_NN with_IN positive_JJ scores_NNS in_IN all_DT areas_NNS covered_VBD ._.
In_IN addition_NN that_IN we_PRP support_VBP the_DT UNs_NNP Universal_NNP Declaration_NNP of_IN Human_NNP 91_CD %_NN of_IN respondents_NNS indicated_VBD that_IN they_PRP were_VBD proud_JJ to_TO work_VB Rights_NNS and_CC states_NNS that_IN we_PRP will_MD only_RB work_VB with_IN suppliers_NNS for_IN the_DT Smith_NNP &_CC Nephew_NNP group_NN ._.
Significant_JJ improvements_NNS who_WP adhere_VBP to_TO business_NN principles_NNS and_CC health_NN ,_, safety_NN ,_, social_JJ over_IN 10_CD %_NN increase_NN in_IN scores_NNS in_IN many_JJ areas_NNS were_VBD seen_VBN and_CC environmental_JJ standards_NNS consistent_JJ with_IN our_PRP$ own_JJ ._.
compared_VBN with_IN the_DT Year_NN 2000_CD results_NNS particularly_RB in_IN Specifically_RB ,_, these_DT prohibit_VBP the_DT use_NN of_IN forced_VBN ,_, compulsory_JJ management_NN style_NN ,_, communication_NN with_IN employees_NNS ,_, or_CC child_NN labor_NN ._.
anticipating_VBG change_NN and_CC the_DT way_NN people_NNS feel_VBP about_IN their_PRP$ job_NN ,_, confirming_VBG that_IN we_PRP have_VBP made_VBN good_JJ progress_NN in_IN all_DT areas_NNS Economic_JJ impact_NN over_IN the_DT past_JJ two_CD years_NNS ._.
But_CC we_PRP still_RB have_VBP work_NN to_TO do_VB :_: Our_PRP$ business_NN policies_NNS aim_VBP to_TO achieve_VB long-term_JJ growth_NN and_CC scores_NNS for_IN questions_NNS about_IN promotion_NN and_CC reward_NN were_VBD profits_NNS which_WDT in_IN turn_NN bring_VBP continued_JJ economic_JJ benefits_NNS to_TO still_RB lower_JJR than_IN we_PRP would_MD like_VB and_CC this_DT will_MD stimulate_VB action_NN shareholders_NNS ,_, employees_NNS ,_, suppliers_NNS and_CC local_JJ communities_NNS ._.
Our_PRP$ sustainable_JJ development_NN depends_VBZ ultimately_RB on_IN our_PRP$ ability_NN to_TO provide_VB a_DT satisfactory_JJ return_NN :_: in_IN 2002_CD we_PRP generated_VBD The_DT communications_NNS functions_NNS at_IN our_PRP$ group_NN head_NN office_NN ,_, an_DT operating_NN return_NN on_IN capital_NN employed_VBN of_IN 29_CD %_NN ._.
group_NN research_NN center_NN and_CC global_JJ business_NN units_NNS work_VBP closely_RB with_IN the_DT Human_NNP Resources_NNPS departments_NNS at_IN each_DT We_PRP continue_VBP to_TO invest_VB in_IN comprehensive_JJ R&D_NN programs_NNS site_NN on_IN all_DT forms_NNS of_IN internal_JJ communication_NN ._.
Our_PRP$ linked_VBN focused_VBN on_IN delivering_VBG better_JJR outcomes_NNS for_IN patients_NNS and_CC business_NN unit_NN and_CC corporate_JJ intranets_NNS are_VBP increasingly_RB well_RB improvements_NNS in_IN application_NN and_CC use_NN for_IN practitioners_NNS ._.
used_VBN ,_, allowing_VBG easy_JJ two-way_JJ communication_NN worldwide_NN and_CC Importantly_RB ,_, we_PRP also_RB aim_VBP to_TO deliver_VB overall_JJ cost_NN savings_NNS increasing_VBG peoples_NNS awareness_NN of_IN financial_JJ ,_, economic_JJ and_CC to_TO healthcare_NN systems_NNS through_IN such_JJ benefits_NNS as_IN reduced_JJ market_NN factors_NNS affecting_VBG company_NN performance_NN ._.
Electronic_JJ dressing_VBG changes_NNS and_CC shorter_JJR operating_NN theater_NN times_NNS ._.
communication_NN in_IN general_JJ continues_VBZ to_TO reduce_VB internal_JJ Our_PRP$ products_NNS seek_VBP to_TO reduce_VB patients_NNS time_NN in_IN hospital_NN paperwork_NN throughout_IN the_DT company_NN ._.
and_CC return_VB them_PRP to_TO health_NN faster_RBR ,_, potentially_RB improving_VBG their_PRP$ productivity_NN and_CC bringing_VBG broader_JJR social_JJ and_CC Community_NNP We_PRP recognize_VBP a_DT strong_JJ obligation_NN to_TO contribute_VB economic_JJ benefits_NNS ._.
to_TO the_DT communities_NNS in_IN which_WDT we_PRP operate_VBP ._.
We_PRP encourage_VBP and_CC support_VBP employees_NNS at_IN all_DT levels_NNS who_WP undertake_VBP community_NN work_NN ,_, providing_VBG resources_NNS and_CC paid_VBN time_NN off_IN to_TO participate_VB in_IN projects_NNS ._.
We_PRP support_VBP a_DT range_NN of_IN charitable_JJ causes_NNS ,_, mainly_RB at_IN local_JJ level_NN ,_, by_IN donations_NNS of_IN money_NN ,_, gifts_NNS in_IN kind_NN and_CC employee_NN time_NN ._.
The_DT company_NN is_VBZ a_DT member_NN of_IN UK_NNP Business_NNP in_IN the_DT Community_NNP and_CC we_PRP are_VBP committed_VBN to_TO corporate_JJ community_NN involvement_NN across_IN the_DT whole_JJ group_NN wherever_WRB practical_JJ ._.
Of_IN course_NN ,_, we_PRP are_VBP also_RB committed_VBN to_TO meeting_VBG our_PRP$ community_NN obligations_NNS under_IN the_DT law_NN ._.
Examples_NNS of_IN the_DT programs_NNS we_PRP support_VBP around_IN our_PRP$ manufacturing_NN sites_NNS can_MD be_VB found_VBN in_IN the_DT Performance_NNP section_NN of_IN the_DT Sustainability_NNP Report_NNP on_IN our_PRP$ website_NN ._.
In_IN 2002_CD our_PRP$ direct_JJ donations_NNS to_TO charitable_JJ and_CC community_NN activities_NNS totalled_VBD 804,000_CD ,_, of_IN which_WDT 400,000_CD went_VBD to_TO the_DT Smith_NNP &_CC Nephew_NNP Foundation_NNP to_TO fund_VB individual_JJ research_NN for_IN doctors_NNS and_CC nurses_NNS ._.
During_IN the_DT year_NN ,_, we_PRP restructured_VBD the_DT Foundation_NNP to_TO focus_VB solely_RB on_IN nursing_NN research_NN where_WRB it_PRP makes_VBZ a_DT major_JJ contribution_NN in_IN the_DT UK_NNP ._.
We_PRP again_RB made_VBD no_DT political_JJ contributions_NNS in_IN 2002_CD ._.
Customers_NNS Educational_NNP support_NN to_TO the_DT medical_JJ community_NN which_WDT we_PRP serve_VBP is_VBZ an_DT integral_JJ part_NN of_IN the_DT way_NN we_PRP do_VBP business_NN ._.
All_DT three_CD of_IN our_PRP$ business_NN units_NNS run_VBP extensive_JJ educational_JJ programs_NNS ranging_VBG from_IN seminars_NNS and_CC dedicated_VBN training_NN facilities_NNS to_TO web-based_JJ information_NN sites_NNS ._.
During_IN 2002_CD our_PRP$ Endoscopy_JJ business_NN alone_RB hosted_VBD 144_CD courses_NNS ,_, training_NN over_IN 1,700_CD surgeons_NNS ._.
Smith_NNP &_CC Nephew_NNP 2002_CD 13_CD Corporate_JJ governance_NN The_DT Board_NNP is_VBZ committed_VBN to_TO the_DT highest_JJS standards_NNS of_IN Shareholders_NNS corporate_JJ governance_NN and_CC considers_VBZ that_IN the_DT company_NN The_DT group_NN issues_NNS summary_NN financial_JJ statements_NNS in_IN place_NN of_IN has_VBZ complied_VBN throughout_IN the_DT year_NN with_IN the_DT Combined_VBN full_JJ annual_JJ accounts_NNS unless_IN shareholders_NNS request_VBP the_DT latter_JJ ._.
Code_NNP of_IN Best_JJS Practice_NN on_IN Corporate_JJ Governance_NN ._.
The_DT summary_NN financial_JJ statement_NN is_VBZ received_VBN by_IN over_IN 90_CD %_NN The_DT Board_NNP of_IN shareholders_NNS ._.
At_IN the_DT half_NN year_NN ,_, an_DT interim_JJ report_NN is_VBZ sent_VBN The_DT Board_NNP meets_VBZ regularly_RB during_IN the_DT year_NN and_CC is_VBZ to_TO all_DT shareholders_NNS ._.
A_DT copy_NN of_IN the_DT full_JJ annual_JJ accounts_NNS is_VBZ responsible_JJ for_IN the_DT strategic_JJ direction_NN ,_, policies_NNS and_CC overall_JJ available_JJ on_IN the_DT Smith_NNP &_CC Nephew_NNP website_NN along_IN with_IN press_NN management_NN of_IN the_DT group_NN ._.
There_EX is_VBZ a_DT clear_JJ division_NN of_IN releases_NNS ,_, institutional_JJ presentations_NNS and_CC audio_JJ webcasts_NNS ._.
responsibilities_NNS between_IN the_DT Chairman_NNP and_CC Chief_NNP Executive_NNP ._.
There_EX are_VBP regular_JJ dialogues_NNS with_IN individual_JJ institutional_JJ The_NNP Board_NNP consists_VBZ of_IN an_DT independent_JJ non-executive_JJ shareholders_NNS ,_, together_RB with_IN results_NNS presentations_NNS twice_RB a_DT Chairman_NNP ,_, two_CD executive_JJ directors_NNS and_CC six_CD independent_JJ year_NN ._.
There_EX is_VBZ an_DT opportunity_NN for_IN individual_JJ shareholders_NNS to_TO non-executive_JJ directors_NNS ._.
All_DT directors_NNS have_VBP full_JJ and_CC timely_JJ question_NN directors_NNS at_IN the_DT AGM_NNP and_CC the_DT company_NN regularly_RB access_NN to_TO all_DT relevant_JJ information_NN and_CC independent_JJ responds_VBZ to_TO letters_NNS from_IN shareholders_NNS on_IN a_DT range_NN of_IN issues_NNS ._.
Non-executive_JJ directors_NNS meet_VBP regularly_RB without_IN management_NN in_IN attendance_NN and_CC appropriate_JJ Risk_NN management_NN &_CC internal_JJ control_NN induction_NN programs_NNS are_VBP offered_VBN to_TO new_JJ directors_NNS ._.
The_DT Board_NNP is_VBZ responsible_JJ for_IN the_DT maintenance_NN of_IN the_DT groups_NNS systems_NNS of_IN risk_NN management_NN and_CC internal_JJ control_NN and_CC for_IN The_DT Board_NNP is_VBZ assisted_VBN by_IN the_DT following_VBG committees_NNS :_: reviewing_VBG their_PRP$ effectiveness_NN ._.
An_DT ongoing_JJ process_NN has_VBZ been_VBN in_IN place_NN for_IN the_DT full_JJ year_NN identifying_VBG ,_, evaluating_VBG and_CC managing_VBG The_DT Audit_NNP Committee_NNP The_NNP Audit_NNP Committee_NNP monitors_VBZ key_JJ risks_NNS through_IN a_DT Risk_NNP Committee_NNP which_WDT reports_VBZ to_TO the_DT the_DT operation_NN and_CC effectiveness_NN of_IN internal_JJ financial_JJ controls_NNS Board_NNP annually_RB ,_, and_CC by_IN a_DT system_NN of_IN functional_JJ reports_NNS to_TO and_CC ensures_VBZ that_IN the_DT accounts_NNS meet_VBP statutory_JJ and_CC other_JJ the_DT Board_NNP and_CC the_DT review_NN of_IN internal_JJ financial_JJ controls_NNS by_IN requirements_NNS ._.
It_PRP selects_VBZ ,_, determines_VBZ the_DT fees_NNS and_CC reviews_VBZ the_DT Audit_NNP Committee_NNP ._.
the_DT performance_NN ,_, independence_NN and_CC objectivity_NN of_IN the_DT auditors_NNS ._.
All_DT non-audit_JJ work_NN is_VBZ pre-approved_JJ by_IN These_DT procedures_NNS are_VBP designed_VBN to_TO identify_VB and_CC manage_VB the_DT committee_NN ._.
those_DT risks_NNS that_WDT could_MD adversely_RB impact_VB the_DT achievement_NN of_IN the_DT groups_NNS objectives_NNS ._.
Whilst_IN they_PRP do_VBP not_RB provide_VB The_DT Remuneration_NNP Committee_NNP The_NNP Remuneration_NNP absolute_JJ assurance_NN against_IN material_NN misstatements_NNS or_CC loss_NN ,_, Committee_NNP sets_VBZ the_DT pay_NN and_CC benefits_NNS of_IN the_DT executive_NN the_DT directors_NNS ,_, following_VBG a_DT review_NN of_IN the_DT systems_NNS described_VBD directors_NNS and_CC members_NNS of_IN the_DT Group_NNP Executive_NNP Committee_NNP ,_, are_VBP of_IN the_DT opinion_NN that_WDT proper_JJ systems_NNS of_IN risk_NN management_NN approves_VBZ their_PRP$ main_JJ terms_NNS of_IN employment_NN and_CC determines_VBZ and_CC internal_JJ control_NN are_VBP in_IN place_NN within_IN the_DT group_NN ._.
share_NN options_NNS and_CC long-term_JJ incentive_NN arrangements_NNS ._.
It_PRP also_RB reviews_VBZ management_NN succession_NN planning_NN ._.
Share_NN capital_NN The_DT company_NN has_VBZ been_VBN informed_VBN of_IN the_DT following_VBG interests_NNS The_DT Nominations_NNPS Committee_NNP The_DT Nominations_NNP Committee_NNP in_IN its_PRP$ ordinary_JJ share_NN capital_NN as_IN at_IN 7_CD February_NNP 2003_CD :_: oversees_VBZ plans_NNS for_IN Board_NNP succession_NN and_CC recommends_VBZ appointments_NNS to_TO the_DT Board_NNP ._.
AXA_NNP Investment_NNP Management_NNP 9.0_CD %_NN Fidelity_NNP 7.1_CD %_NN The_DT Group_NNP Executive_NNP Committee_NNP The_NNP Group_NNP Executive_NNP Legal_NNP &_CC General_NNP Investment_NNP Management_NNP 3.4_CD %_NN Committee_NNP assists_VBZ the_DT Chief_NNP Executive_NNP in_IN the_DT management_NN of_IN the_DT group_NN ._.
At_IN the_DT AGM_NNP ,_, the_DT company_NN will_MD be_VB seeking_VBG a_DT renewal_NN of_IN its_PRP$ current_JJ permission_NN from_IN shareholders_NNS to_TO purchase_VB its_PRP$ own_JJ The_DT terms_NNS of_IN reference_NN of_IN the_DT Audit_NNP ,_, Remuneration_NNP and_CC shares_NNS ._.
No_DT shares_NNS have_VBP been_VBN purchased_VBN or_CC contracted_VBN for_IN Nominations_NNP Committees_NNS may_MD be_VB found_VBN at_IN www_NN ._.
smithor_NN are_VBP the_DT subject_NN of_IN an_DT option_NN under_IN the_DT expiring_VBG authority_NN ._.
Auditors_NNS Membership_NN of_IN Board_NNP committees_NNS and_CC of_IN the_DT Group_NNP Ernst_NNP &_CC Young_NNP LLP_NNP have_VBP expressed_VBN their_PRP$ willingness_NN Executive_NNP Committee_NNP is_VBZ shown_VBN with_IN the_DT biographical_JJ to_TO continue_VB as_IN auditors_NNS and_CC a_DT resolution_NN proposing_VBG their_PRP$ details_NNS of_IN directors_NNS on_IN pages_NNS 10_CD and_CC 11_CD ._.
reappointment_NN will_MD be_VB put_VBN to_TO the_DT AGM_NNP ._.
Directors_NNS All_DT directors_NNS are_VBP subject_JJ to_TO re-election_NN every_DT three_CD years_NNS ,_, and_CC in_IN accordance_NN with_IN the_DT Articles_NNPS of_IN Association_NNP ,_, Dudley_NNP Eustace_NNP and_CC Peter_NNP Hooley_NNP retire_VB by_IN rotation_NN and_CC ,_, being_VBG eligible_JJ offer_NN themselves_PRP for_IN re-election_NN at_IN the_DT forthcoming_JJ AGM_NNP ._.
Sir_NNP Timothy_NNP Lankester_NNP will_MD be_VB retiring_VBG at_IN the_DT AGM_NNP but_CC will_MD not_RB be_VB offering_VBG himself_PRP for_IN re-election_NN ._.
No_DT director_NN had_VBD a_DT material_NN beneficial_JJ interest_NN in_IN any_DT contract_NN involving_VBG the_DT company_NN or_CC its_PRP$ subsidiaries_NNS in_IN 2002_CD ._.
14_CD Smith_NNP &_CC Nephew_NNP 2002_CD Summary_NNP remuneration_NN report_NN Remuneration_NNP policy_NN The_DT Remuneration_NNP Committee_NNP policy_NN for_IN this_DT and_CC future_JJ years_NNS is_VBZ to_TO ensure_VB that_IN remuneration_NN is_VBZ sufficiently_RB competitive_JJ to_TO attract_VB ,_, retain_VB and_CC motivate_VB executive_JJ directors_NNS and_CC Group_NNP Executive_NNP Committee_NNP members_NNS of_IN a_DT calibre_NN that_WDT meets_VBZ the_DT groups_NNS needs_VBZ to_TO achieve_VB its_PRP$ performance_NN against_IN financial_JJ objectives_NNS and_CC relevant_JJ competitors_NNS practice_NN ._.
Remuneration_NNP throughout_IN the_DT group_NN is_VBZ designed_VBN to_TO be_VB competitive_JJ in_IN the_DT country_NN of_IN employment_NN ._.
The_DT committee_NN gives_VBZ full_JJ consideration_NN to_TO the_DT requirements_NNS in_IN Schedule_NNP A_NNP of_IN the_DT Combined_NNP Code_NNP ._.
Directors_NNS incentive_NN plans_VBZ Executive_NNP directors_NNS participate_VB in_IN an_DT annual_JJ bonus_NN scheme_NN based_VBN on_IN annual_JJ growth_NN in_IN adjusted_JJ earnings_NNS per_IN share_NN after_IN deducting_VBG goodwill_NN amortisation_NN and_CC return_NN on_IN capital_NN employed_VBN ,_, and_CC in_IN a_DT long-term_JJ incentive_NN plan_NN LTIP_NNP based_VBN on_IN the_DT companys_NNS total_JJ shareholder_NN return_NN TSR_NNP in_IN relation_NN to_TO 41_CD UK_NNP listed_VBN manufacturing_NN companies_NNS with_IN substantial_JJ international_JJ activities_NNS ,_, and_CC growth_NN in_IN earnings_NNS per_IN share_NN over_IN a_DT three_CD year_NN period_NN ._.
The_DT performance_NN conditions_NNS were_VBD identified_VBN as_IN those_DT which_WDT represented_VBD a_DT fair_JJ measure_NN of_IN the_DT companys_NNS performance_NN and_CC would_MD reflect_VB increase_NN in_IN shareholder_NN value_NN ._.
The_DT companys_NNS TSR_NNP performance_NN and_CC its_PRP$ performance_NN relative_JJ to_TO the_DT comparator_NN group_NN is_VBZ monitored_VBN by_IN independent_JJ consultants_NNS ._.
Total_JJ outstanding_JJ conditional_JJ awards_NNS of_IN shares_NNS under_IN the_DT LTIP_NNP are_VBP :_: Christopher_NNP ODonnell_NNP 386,488_CD 2001_CD 448,649_CD and_CC Peter_NNP Hooley_NNP 236,824_CD 2001_CD 282,965_CD ._.
For_IN the_DT three_CD year_NN plan_NN period_NN commencing_VBG 2000_CD the_DT companys_NNS TSR_NNP of_IN 147.36_CD %_NN was_VBD ranked_VBN first_RB in_IN the_DT comparator_NN group_NN and_CC the_DT earnings_NNS per_IN share_NN performance_NN criterion_NN was_VBD met_VBN ,_, enabling_VBG the_DT plan_NN participants_NNS to_TO be_VB eligible_JJ for_IN 100_CD %_NN of_IN the_DT shares_NNS conditionally_RB awarded_VBN in_IN 2000_CD ._.
As_IN a_DT result_NN ,_, on_IN 7_CD February_NNP 2003_CD ,_, Christopher_NNP ODonnell_NNP became_VBD entitled_VBN to_TO 155,065_CD shares_NNS and_CC Peter_NNP Hooley_NNP entitled_VBD to_TO 96,916_CD shares_NNS which_WDT are_VBP included_VBN in_IN the_DT outstanding_JJ conditional_JJ awards_NNS of_IN shares_NNS above_IN ._.
Executive_NNP directors_NNS were_VBD last_JJ granted_VBN options_NNS under_IN executive_JJ share_NN option_NN schemes_NNS in_IN 1996_CD which_WDT were_VBD not_RB subject_JJ to_TO performance_NN conditions_NNS ,_, but_CC under_IN the_DT LTIP_NNP ,_, shares_NNS that_WDT have_VBP vested_VBN may_MD be_VB taken_VBN in_IN the_DT form_NN of_IN nil-cost_JJ options_NNS and_CC exercised_VBN at_IN a_DT later_JJ date_NN ._.
UK_NNP directors_NNS are_VBP eligible_JJ to_TO participate_VB in_IN the_DT savings_NNS related_VBN share_NN option_NN scheme_NN ._.
As_IN a_DT component_NN company_NN of_IN the_DT FTSE_NNP 100_CD index_NN ,_, a_DT graph_NN of_IN the_DT companys_NNS TSR_NNP performance_NN compared_VBN to_TO that_DT of_IN the_DT TSR_NNP of_IN the_DT index_NN can_MD be_VB found_VBN on_IN page_NN 2_CD ._.
Service_NNP contracts_NNS Executive_NNP directors_NNS ,_, in_IN line_NN with_IN group_NN policy_NN ,_, have_VBP notice_NN periods_NNS of_IN 12_CD months_NNS ._.
All_DT new_JJ appointments_NNS are_VBP intended_VBN to_TO have_VB 12_CD months_NNS notice_NN periods_NNS ,_, but_CC it_PRP is_VBZ recognized_VBN that_IN for_IN some_DT appointments_NNS a_DT longer_JJR period_NN may_MD initially_RB be_VB necessary_JJ for_IN competitive_JJ reasons_NNS ,_, reducing_VBG to_TO 12_CD months_NNS thereafter_RB ._.
Christopher_NNP ODonnell_NNP and_CC Peter_NNP Hooley_NNP have_VBP contracts_NNS terminable_JJ by_IN the_DT company_NN on_IN not_RB more_JJR than_IN 12_CD months_NNS notice_NN and_CC by_IN the_DT director_NN on_IN 6_CD months_NNS notice_NN ._.
Termination_NN of_IN the_DT contract_NN by_IN the_DT company_NN would_MD entitle_VB the_DT executive_NN directors_NNS to_TO 12_CD months_NNS basic_JJ salary_NN ,_, bonus_NN at_IN target_NN of_IN 30_CD %_NN ,_, a_DT contribution_NN of_IN 30_CD %_NN of_IN salary_NN to_TO reflect_VB the_DT loss_NN of_IN pension_NN benefits_NNS ,_, an_DT amount_NN to_TO cover_VB other_JJ benefits_NNS and_CC a_DT time_NN apportionment_NN of_IN the_DT LTIP_NNP entitlement_NN ._.
Non-executive_JJ directors_NNS do_VBP not_RB have_VB service_NN contracts_NNS and_CC are_VBP normally_RB appointed_VBN for_IN terms_NNS of_IN three_CD years_NNS terminable_JJ at_IN will_MD ,_, without_IN notice_NN by_IN either_CC the_DT company_NN or_CC the_DT director_NN and_CC without_IN compensation_NN ._.
Their_PRP$ remuneration_NN is_VBZ determined_VBN by_IN the_DT Nominations_NNPS Committee_NNP ._.
Directors_NNS emoluments_NNS and_CC share_NN interests_NNS Total_JJ emoluments_NNS Share_NN interests_NNS 2002_CD 2001_CD 31_CD December_NNP 2002_CD 1_CD January_NNP 2002 000 000_CD Shares_NNP Options_NNPS Shares_NNP Options_NNPS Chairman_NNP :_: D._NNP G._NNP Eustace_NNP 170_CD 170_CD 49,679_CD 40,909_CD Executive_NNP :_: C._NNP J._NNP ODonnell_NNP 890 790 122_CD ,136_CD 517,495_CD 120,703_CD 331,263_CD P._NNP Hooley_NNP 583 545 111_CD ,571_CD 450,682_CD 58,789_CD 423,723_CD NonSir_NNP Timothy_NNP Lankester_NNP 30_CD 30_CD 6,096_CD 6,035_CD executive_NN :_: Dr_NNP R._NNP W._NNP H._NNP Stomberg_NNP 30_CD 30_CD 6,945_CD 6,864_CD W._NNP D._NNP Knowlton_NNP 30_CD 30_CD 12,501_CD 7,501_CD R._NNP fide_NNP Schutter_NNP 30_CD 30_CD 200,000_CD 100,000_CD Dr_NNP P._NNP Kirby_NNP from_IN 1_CD March_NNP 2002_CD 25_CD B._NNP Larcombe_NNP from_IN 1_CD March_NNP 2002_CD 25_CD Sir_NNP Anthony_NNP Cleaver_NNP to_TO 28_CD Feb_NNP 2002_CD 5_CD 30_CD Sir_NNP Brian_NNP Pearse_NNP to_TO 28_CD Feb_NNP 2002_CD 5_CD 30_CD 1,823_CD 1,685_CD Inclusive_NNP of_IN salaries_NNS and_CC fees_NNS ,_, benefits_NNS ,_, annual_JJ bonus_NN and_CC pension_NN entitlements_NNS ._.
Profits_NNS on_IN exercise_NN of_IN share_NN options_NNS were_VBD 211,950_CD :_: Peter_NNP Hooley_NNP 211,950_CD 2001_CD 197,542_CD :_: Christopher_NNP ODonnell_NNP 22,171_CD ,_, Peter_NNP Hooley_NNP 175,371_CD ._.
Smith_NNP &_CC Nephew_NNP 2002_CD 15_CD Auditors_NNS statement_NN Independent_NNP auditors_NNS statement_NN to_TO the_DT members_NNS of_IN Smith_NNP &_CC Nephew_NNP plc_NN We_PRP have_VBP examined_VBN the_DT groups_NNS summary_NN financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD which_WDT comprises_VBZ summary_NN group_NN profit_NN and_CC loss_NN account_NN ,_, summary_NN group_NN balance_NN sheet_NN and_CC summary_NN group_NN cash_NN flow_NN statement_NN ._.
Respective_JJ responsibilities_NNS of_IN directors_NNS and_CC auditors_NNS The_DT directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT report_NN to_TO shareholders_NNS and_CC summary_NN financial_JJ statement_NN in_IN accordance_NN with_IN applicable_JJ law_NN ._.
This_DT report_NN has_VBZ been_VBN prepared_VBN for_IN the_DT members_NNS of_IN the_DT company_NN pursuant_JJ to_TO Section_NNP 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD the_DT Act_NNP and_CC for_IN no_DT other_JJ purpose_NN ._.
No_DT person_NN is_VBZ entitled_VBN to_TO rely_VB on_IN this_DT report_NN unless_IN such_JJ person_NN :_: i_FW is_VBZ a_DT person_NN who_WP is_VBZ entitled_VBN to_TO rely_VB on_IN this_DT report_NN by_IN virtue_NN of_IN and_CC for_IN the_DT purpose_NN of_IN the_DT Act_NNP :_: or_CC ii_FW has_VBZ been_VBN expressly_RB authorised_VBN to_TO do_VB so_RB by_IN our_PRP$ prior_JJ written_VBN consent_NN ._.
Save_NNP as_IN above_RB ,_, we_PRP do_VBP not_RB accept_VB responsibility_NN for_IN this_DT report_NN to_TO any_DT other_JJ person_NN or_CC for_IN any_DT other_JJ purpose_NN and_CC we_PRP hereby_VBP expressly_RB disclaim_VB any_DT and_CC all_DT such_JJ liability_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN of_IN the_DT summary_NN financial_JJ statement_NN within_IN the_DT report_NN to_TO shareholders_NNS and_CC summary_NN financial_JJ statement_NN with_IN the_DT full_JJ annual_JJ accounts_NNS ,_, directors_NNS report_NN and_CC remuneration_NN report_NN ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT report_NN to_TO the_DT shareholders_NNS and_CC summary_NN financial_JJ statement_NN and_CC consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconsistencies_NNS with_IN the_DT summary_NN financial_JJ statement_NN ._.
Basis_NN of_IN opinion_NN We_PRP conducted_VBD our_PRP$ examination_NN in_IN accordance_NN with_IN Bulletin_NNP 1999_CD 6_CD The_DT auditors_NNS statement_NN on_IN the_DT summary_NN financial_JJ statement_NN issued_VBN by_IN the_DT Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT United_NNP Kingdom_NNP ._.
Opinion_NN In_IN our_PRP$ opinion_NN the_DT summary_NN financial_JJ statement_NN is_VBZ consistent_JJ with_IN the_DT full_JJ annual_JJ accounts_NNS ,_, directors_NNS report_NN and_CC remuneration_NN report_NN of_IN Smith_NNP &_CC Nephew_NNP plc_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD and_CC complies_VBZ with_IN the_DT applicable_JJ requirements_NNS of_IN section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, and_CC regulations_NNS made_VBD thereunder_RB ._.
Ernst_NNP &_CC Young_NNP LLP_NNP Registered_NNP auditor_NN London_NNP ,_, 7_CD February_NNP 2003_CD This_DT summary_NN financial_JJ statement_NN is_VBZ a_DT summary_NN of_IN information_NN in_IN the_DT groups_NNS full_JJ annual_JJ accounts_NNS and_CC was_VBD approved_VBN by_IN the_DT Board_NNP on_IN 7_CD February_NNP 2003_CD and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN Dudley_NNP Eustace_NNP ,_, Christopher_NNP ODonnell_NNP and_CC Peter_NNP Hooley_NNP ._.
It_PRP does_VBZ not_RB contain_VB sufficient_JJ information_NN to_TO allow_VB a_DT full_JJ understanding_NN of_IN the_DT results_NNS of_IN the_DT group_NN and_CC state_NN of_IN affairs_NNS of_IN the_DT company_NN or_CC of_IN the_DT group_NN ._.
A_DT review_NN of_IN the_DT business_NN is_VBZ included_VBN in_IN the_DT directors_NNS report_NN ._.
The_DT report_NN of_IN the_DT auditors_NNS on_IN the_DT full_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD was_VBD unqualified_JJ and_CC did_VBD not_RB contain_VB a_DT statement_NN made_VBN under_IN either_DT section_NN 237_CD 2_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD accounting_NN records_NNS or_CC returns_NNS inadequate_JJ or_CC accounts_VBZ not_RB agreeing_VBG with_IN records_NNS or_CC returns_NNS or_CC section_NN 237_CD 3_CD failure_NN to_TO obtain_VB necessary_JJ information_NN and_CC explanations_NNS ._.
For_IN further_JJ information_NN the_DT full_JJ annual_JJ accounts_NNS and_CC the_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS should_MD be_VB consulted_VBN ._.
Shareholders_NNS have_VBP the_DT right_NN to_TO demand_VB ,_, free_JJ of_IN charge_NN ,_, a_DT copy_NN of_IN the_DT groups_NNS full_JJ annual_JJ report_NN and_CC accounts_NNS ,_, which_WDT may_MD be_VB obtained_VBN from_IN the_DT companys_NNS registrars_NNS ._.
16_CD Smith_NNP &_CC Nephew_NNP 2002_CD Summary_NNP financial_JJ statement_NN Group_NNP profit_NN and_CC loss_NN account_NN 2002_CD 2001_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD million_CD million_CD Turnover_NN Ongoing_VBG operations_NNS 1,083.7_CD 943.0_CD Operations_NNP contributed_VBD to_TO the_DT joint_JJ venture_NN 35.3_CD Continuing_VBG operations_NNS 1,083.7_CD 978.3_CD Discontinued_VBN operations_NNS 26.2_CD 103.4_CD Group_NNP turnover_NN 1,109.9_CD 1,081.7_CD Share_NN of_IN joint_JJ venture_NN 155.0_CD 123.6_CD 1,264.9_CD 1,205.3_CD Operating_NN profit_NN Ongoing_VBG operations_NNS :_: Before_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS 196.0_CD 170.8_CD Goodwill_NNP amortisation_NN 17.5_CD 10.4_CD Exceptional_JJ items_NNS 29.9_CD 19.3_CD 148.6_CD 141.1_CD Operations_NNP contributed_VBD to_TO the_DT joint_JJ venture_NN :_: Before_IN exceptional_JJ items_NNS 3.6_CD Exceptional_JJ items_NNS 1.8_CD Continuing_VBG operations_NNS 148.6_CD 142.9_CD Discontinued_VBN operations_NNS 2.1_CD 11.1_CD 150.7_CD 154.0_CD Share_NN of_IN operating_NN profit_NN of_IN the_DT joint_JJ venture_NN :_: Before_IN exceptional_JJ items_NNS 19.6_CD 12.8_CD Exceptional_JJ items_NNS 2.6_CD 5.0_CD 167.7_CD 161.8_CD Share_NN of_IN operating_NN profit_NN of_IN the_DT associated_VBN undertaking_NN 4.9_CD 172.6_CD 161.8_CD Discontinued_VBN operations_NNS net_JJ profit_NN on_IN disposals_NNS 18.0_CD 49.2_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN interest_NN 190.6_CD 211.0_CD Interest_NN payable_JJ 12.7_CD 17.4_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 177.9_CD 193.6_CD Taxation_NNP 65.8_CD 64.0_CD Attributable_JJ profit_NN for_IN the_DT year_NN 112.1_CD 129.6_CD Ordinary_NNP dividends_NNS 44.6_CD 42.9_CD Retained_VBN profit_NN for_IN the_DT year_NN 67.5_CD 86.7_CD Basic_JJ earnings_NNS per_IN ordinary_JJ share_NN 12.11_CD p_VBP 14.07_CD p_JJ Diluted_JJ earnings_NNS per_IN ordinary_JJ share_NN 12.02_CD p_VBP 13.95_CD p_JJ Results_NNS before_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS Profit_NN before_IN taxation_NN 209.9_CD 180.9_CD Adjusted_VBN basic_JJ earnings_NNS per_IN ordinary_JJ share_NN 16.02_CD p_NN 13.96_CD p_NN Adjusted_VBN diluted_JJ earnings_NNS per_IN ordinary_JJ share_NN 15.89_CD p_VBP 13.84_CD p_JJ Smith_NNP &_CC Nephew_NNP 2002_CD 17_CD Summary_NNP financial_JJ statement_NN Group_NNP balance_NN sheet_NN 2002_CD 2001_CD at_IN 31_CD December_NNP 2002_CD million_CD million_CD Intangible_JJ fixed_JJ assets_NNS 317.2_CD 187.8_CD Tangible_JJ fixed_JJ assets_NNS 255.8_CD 245.0_CD Investment_NN in_IN joint_JJ venture_NN 115.0_CD 114.0_CD Investment_NN in_IN associated_VBN undertaking_NN 8.5_CD Investments_NNP 8.2_CD 25.7_CD 704.7_CD 572.5_CD Stocks_NNS 229.5_CD 232.2_CD Debtors_NNS 280.7_CD 266.8_CD Cash_NN 22.5_CD 26.4_CD Creditors_NNS 315.9_CD 342.8_CD 216.8_CD 182.6_CD Borrowings_NNS 316.1_CD 255.2_CD Provisions_NNS 88.1_CD 95.3_CD 517.3_CD 404.6_CD Called_VBN up_RP share_NN capital_NN 113.8_CD 113.4_CD Reserves_NNS 403.5_CD 291.2_CD 517.3_CD 404.6_CD Group_NNP cash_NN flow_NN 2002_CD 2001_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD million_CD million_CD Operating_NN profit_NN 150.7_CD 154.0_CD Depreciation_NN ,_, amortisation_NN and_CC exceptional_JJ write-off_NN #_# 94.4_CD 60.3_CD Working_JJ capital_NN and_CC provisions_NNS 35.8_CD 22.4_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 209.3_CD 191.9_CD Capital_NN expenditure_NN and_CC financial_JJ investment_NN 86.1_CD 72.6_CD Operating_NN cash_NN flow_NN 123.2_CD 119.3_CD Joint_NNP venture_NN dividend_NN 3.9_CD Interest_NN 10.2_CD 16.5_CD Tax_NNP paid_VBD 52.3_CD 76.2_CD Dividends_NNPS paid_VBD 43.5_CD 42.0_CD Acquisitions_NNS 206.3_CD 69.3_CD Disposals_NNS 71.8_CD 61.7_CD Joint_NNP venture_NN formation_NN 5.7_CD 12.6_CD Issues_NNS of_IN ordinary_JJ share_NN capital_NN 6.1_CD 9.0_CD Net_JJ cash_NN flow_NN 101.6_CD 1.4_CD Exchange_NNP adjustments_NNS 68.2_CD 5.8_CD Opening_NN net_JJ debt_NN 243.5_CD 236.3_CD Closing_NN net_JJ debt_NN 276.9_CD 243.5_CD #Includes_NNS goodwill_NN amortisaton_NN of_IN 17.5_CD m_NN 2001_CD 10.4_CD m_NN and_CC 17.5_CD m_JJ write-off_NN of_IN the_DT groups_NNS equity_NN investment_NN in_IN Advanced_NNP Tissue_NNP Sciences_NNPS ,_, Inc._NNP ._.
After_IN 19.3_CD m_NN 2001_CD 23.5_CD m_NN of_IN outgoings_NNS on_IN rationalisation_NN ,_, acquisition_NN integration_NN and_CC divestment_NN costs_NNS ._.
Net_JJ debt_NN includes_VBZ 16.7_CD m_NN of_IN net_JJ currency_NN swap_NN assets_NNS 2001_CD net_JJ currency_NN swap_NN liabilities_NNS of_IN 14.7_CD m._FW 18_CD Smith_NNP &_CC Nephew_NNP 2002_CD Information_NN for_IN shareholders_NNS Financial_JJ calendar_NN Shareview_NNP To_TO view_VB information_NN about_IN your_PRP$ shareholdings_NNS on_IN the_DT internet_NN ,_, register_NN at_IN www_NN ._.
Smith_NNP &_CC Nephew_NNP 2002_CD 19_CD Group_NNP five_CD year_NN summary_NN 2002 2001 2000 1999_CD #_# 1998_CD #_# Profit_NN and_CC loss_NN account_NN million_CD million_CD million_CD million_CD million_CD Turnover_NN Continuing_VBG operations_NNS 1,083.7_CD 978.3_CD 911.5_CD 799.9_CD 713.6_CD Discontinued_VBN operations_NNS 26.2_CD 103.4_CD 223.2_CD 320.0_CD 339.8_CD Group_NNP turnover_NN 1,109.9_CD 1,081.7_CD 1,134.7_CD 1,119.9_CD 1,053.4_CD Share_NN of_IN joint_JJ venture_NN 155.0_CD 123.6_CD 1,264.9_CD 1,205.3_CD 1,134.7_CD 1,119.9_CD 1,053.4_CD Operating_NN profit_NN Continuing_VBG operations_NNS :_: Before_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS 196.0_CD 174.4_CD 156.9_CD 122.7_CD 106.5_CD Goodwill_NNP amortisation_NN 17.5_CD 10.4_CD 6.9_CD 1.8_CD 0.3_CD Exceptional_JJ items_NNS 29.9_CD 21.1_CD 12.4_CD 40.1_CD 15.9_CD Discontinued_VBN operations_NNS :_: Before_IN exceptional_JJ items_NNS 2.1_CD 11.1_CD 29.0_CD 46.6_CD 47.9_CD Exceptional_JJ items_NNS 3.9_CD 11.6_CD 2.0_CD 150.7_CD 154.0_CD 162.7_CD 115.8_CD 136.2_CD Share_NN of_IN operating_NN profit_NN of_IN the_DT joint_JJ venture_NN :_: Before_IN exceptional_JJ items_NNS 19.6_CD 12.8_CD Exceptional_JJ items_NNS 2.6_CD 5.0_CD 167.7_CD 161.8_CD 162.7_CD 115.8_CD 136.2_CD Share_NN of_IN operating_NN profit_NN of_IN the_DT associated_VBN undertaking_NN 4.9_CD 172.6_CD 161.8_CD 162.7_CD 115.8_CD 136.2_CD Profit_NN on_IN disposals_NNS 18.0_CD 49.2_CD 109.5_CD 62.9_CD Profit_NN before_IN interest_NN 190.6_CD 211.0_CD 272.2_CD 178.7_CD 136.2_CD Interest_NN payable_JJ receivable_JJ 12.7_CD 17.4_CD 7.0_CD 3.4_CD 1.7_CD Profit_NN before_IN taxation_NN 177.9_CD 193.6_CD 265.2_CD 182.1_CD 134.5_CD Taxation_NNP 65.8_CD 64.0_CD 57.7_CD 77.3_CD 40.8_CD Profit_NN after_IN taxation_NN 112.1_CD 129.6_CD 207.5_CD 104.8_CD 93.7_CD Ordinary_NNP dividends_NNS 44.6_CD 42.9_CD 41.3_CD 72.5_CD 69.2_CD Special_JJ dividend_NN 415.6_CD Retained_VBN profit_NN deficit_NN 67.5_CD 86.7_CD 249.4_CD 32.3_CD 24.5_CD Basic_JJ earnings_NNS per_IN ordinary_JJ share_NN 12.11_CD p_VBP 14.07_CD p_JJ 20.07_CD p_NN 9.39_CD p_VBP 8.42_CD p_JJ Diluted_JJ earnings_NNS per_IN ordinary_JJ share_NN 12.02_CD p_VBP 13.95_CD p_JJ 19.95_CD p_NN 9.37_CD p_NN 8.40_CD p_NN Dividends_NNS per_IN ordinary_JJ share_NN 4.80_CD p_VBP 4.65_CD p_JJ 4.50_CD p_NN 6.50_CD p_NN 6.20_CD p_NN Results_NNS before_IN goodwill_NN amortisation_NN and_CC exceptional_JJ items_NNS :_: Profit_NN before_IN taxation_NN 209.9_CD 180.9_CD 178.9_CD 172.7_CD 152.7_CD Adjusted_VBN earnings_NNS per_IN ordinary_JJ share_NN 16.02_CD p_NN 13.96_CD p_NN 12.19_CD p_VBP 10.88_CD p_JJ 9.61_CD p_NN Adjusted_VBN diluted_JJ earnings_NNS per_IN ordinary_JJ share_NN 15.89_CD p_VBP 13.84_CD p_JJ 12.12_CD p_NN 10.85_CD p_VBP 9.60_CD p_JJ Operating_NN profit_NN before_IN goodwill_NN amortisation_NN and_CC 17.8_CD %_NN 17.1_CD %_NN 16.4_CD %_NN 15.1_CD %_NN 14.7_CD %_NN exceptional_JJ items_NNS to_TO group_NN sales_NNS Research_NN and_CC development_NN costs_NNS to_TO group_NN sales_NNS 5.5_CD %_NN 4.7_CD %_NN 4.0_CD %_NN 4.0_CD %_NN 4.1_CD %_NN Capital_NN investment_NN including_VBG intangibles_NNS to_TO group_NN sales_NNS 7.7_CD %_NN 6.9_CD %_NN 5.6_CD %_NN 5.8_CD %_NN 6.6_CD %_NN #_# 1999_CD and_CC 1998_CD have_VBP not_RB been_VBN restated_VBN for_IN FRS_NNP 19_CD ._.
You_PRP have_VBP access_NN to_TO more_JJR information_NN from_IN the_DT following_JJ sources_NNS :_: Board_NNP Group_NNP Executive_NNP Committee_NNP biographies_NNS For_IN further_JJ biographies_NNS ,_, visit_NN :_: www_NN ._.
html_NN You_PRP are_VBP here_RB :_: Report_NNP to_TO Shareholders_NNS and_CC Summary_NNP Financial_NNP Statement_NNP Contents_NNP Financial_NNP highlights_VBZ Chairmans_NNP statement_NN Chief_NNP Executives_NNS statement_NN Board_NNP &_CC Group_NNP Executive_NNP Committee_NNP Corporate_NNP social_JJ responsibility_NN Corporate_JJ governance_NN Summary_NNP remuneration_NN report_NN Auditors_NNS statement_NN Summary_NNP financial_JJ statement_NN Annual_JJ Report_NNP and_CC Accounts_NNPS Information_NNP for_IN shareholders_NNS For_IN detailed_JJ financial_JJ information_NN Group_NNP five_CD year_NN summary_NN you_PRP can_MD request_VB a_DT full_JJ printed_VBN Annual_JJ Report_NNP and_CC Accounts_NNPS or_CC visit_NN :_: www_NN ._.
com_NN investors_NNS annualreport2002_JJ Available_JJ as_IN a_DT printed_VBN document_NN or_CC online_NN at_IN :_: www_NN ._.
